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Statistical Methods For Paired Transplant Genetic Data
Abstract
Transplant matching for donor and recipient is traditionally based on various clinical aspects, and any
genetic matching focuses only on the major histocompatibility complex (MHC) of the genome, which
codes for a large set of immune genes. Due to a lack of improvement in long-term transplant outcomes
over the years, there has been a recent push to look beyond the MHC at other genomic regions that may
be important for donor/recipient matching. Unfortunately, no clear definition of genetic matching distance
between a donor/recipient pair has been established in the field, and association results may differ based
on what measure is used for analysis. In this work, we focus on establishing and testing various
statistical methods that can be applied to paired donor/recipient genetic data. First, we focus on genetic
matching at a single genetic variant, examining four different genetic matching scores. Our work shows
that jointly testing the recipient genotype variant and matching score is a powerful preliminary screening
method to discover transplant outcome related variants. Following-up with marginal testing can then lead
to more insight on potential biological mechanisms behind transplant outcomes. Application of these
methods to liver transplant data analysis found various genetic variants where a genetic matching score
was associated with time to acute rejection. Building on this work, we then propose a multi-marker Joint
Score Test (JST) to jointly test for association between recipient genotypes and a gene-based donor/
recipient matching score with transplant outcome. Extensive simulation studies show JST is competitive
when compared with existing methods, especially when the associated variants are in low linkage
disequilibrium with the rest of the variants in the region. Applying JST to paired kidney transplant data
gave insight into gene regions that are potentially associated with acute rejection outcome. Lastly,
focusing on association testing of genetic matching score only, we investigated the performance of four
existing high-dimensional data methods that allow us to account for a potentially large number of
recipient genotype variant effects.
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ABSTRACT
STATISTICAL METHODS FOR PAIRED TRANSPLANT GENETIC DATA
Victoria Arthur
Jinbo Chen
Transplant matching for donor and recipient is traditionally based on various clinical aspects, and
any genetic matching focuses only on the major histocompatibility complex (MHC) of the genome,
which codes for a large set of immune genes. Due to a lack of improvement in long-term
transplant outcomes over the years, there has been a recent push to look beyond the MHC at
other genomic regions that may be important for donor/recipient matching. Unfortunately, no clear
definition of genetic matching distance between a donor/recipient pair has been established in the
field, and association results may differ based on what measure is used for analysis. In this work,
we focus on establishing and testing various statistical methods that can be applied to paired
donor/recipient genetic data. First, we focus on genetic matching at a single genetic variant,
examining four different genetic matching scores. Our work shows that jointly testing the recipient
genotype variant and matching score is a powerful preliminary screening method to discover
transplant outcome related variants. Following-up with marginal testing can then lead to more
insight on potential biological mechanisms behind transplant outcomes. Application of these
methods to liver transplant data analysis found various genetic variants where a genetic matching
score was associated with time to acute rejection. Building on this work, we then propose a multimarker Joint Score Test (JST) to jointly test for association between recipient genotypes and a
gene-based donor/recipient matching score with transplant outcome. Extensive simulation studies
show JST is competitive when compared with existing methods, especially when the associated
variants are in low linkage disequilibrium with the rest of the variants in the region. Applying JST
to paired kidney transplant data gave insight into gene regions that are potentially associated with
acute rejection outcome. Lastly, focusing on association testing of genetic matching score only,
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we investigated the performance of four existing high-dimensional data methods that allow us to
account for a potentially large number of recipient genotype variant effects.
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CHAPTER 1

INTRODUCTION

Successful matching of transplant donors and recipients is based on a combination of factors.
Most of these factors are related to clinical aspects, such as the age and sex of the recipient, the
age, sex, and living or deceased status of the donor, as well as the size and quality of the organ
itself. For some solid organ transplant, such as kidney transplant, genetic factors are also looked
at for donor/recipient (D/R) matching. Genetic matching focuses almost entirely on humanleukocyte antigen (HLA) antigens or epitopes, which are in a section of the human genome that
codes for much of a person’s immune response. For many solid organs, however, HLA matching
is not conducted prior to transplant.
This current approach to D/R matching is not without its share of problems. Multiple studies have
found that organ rejection can occur even in the case of a perfect HLA match between donor and
recipient (Zanoni and Kiryluk, 2020; Grafft et al., 2010). Data also shows that only about one is
five graft losses is directly attributable to HLA mismatch, meaning that around 80% of losses are
due to some unknown cause (Zanoni and Kiryluk, 2020). In addition, while short-term graft
survival has improved over the years, there has been no subsequent improvement in long-term
survival (Farouk, Zhang, and Menon, 2020). To solve these lingering issues, we need to
determine other genetic regions that may be important for D/R matching prior to transplant.
Past genetic studies in transplantation have focused separately on the recipient or the donor
genome. Genome-wide association studies have found various recipient genes to be associated
with transplant outcomes. In kidney transplant, for example, the gene CCR5 was determined to
be associated with acute rejection after transplant (Cha et al., 2009). Recipient genes have also
been found that directly impact immunosuppression metabolism post-transplant, such as ABCB1
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in the liver (Almoguera, Shaked, and Keating, 2014). Separate studies have found donor gene
regions that impact a recipient’s transplant outcome. In their manuscript, Julian et al. (2017)
shows that specific alleles in the APOL1 gene are associated with the probability a donor kidney
will be rejected post-transplant. In liver transplant, genes such as TLR4 have been shown to be
associated with the outcome of acute rejection after transplant (Oetting et al., 2012). Transplant
genetics is unique, however, in that it involves a pair of genomes residing in a single body. By
looking at the recipient and donor genomes together, we may be able to gain additional insight
into genetic modifiers of various transplant outcomes. Our focus in this dissertation is to examine
existing statistical methods that utilize paired D/R genomes and to propose new methods that are
specifically formulated to be used with paired genetic data.
In Chapter 2 we examine matching of single genetic variants between the donor and recipient
genomes. While single variant methods are relatively commonplace for analysis of a single
genome, very few methods have been proposed for paired genetic data. Work on D/R genetic
matching beyond the HLA region is still relatively new, and because of this, there has not been a
systematic study done of the most powerful single variant method considering genetic matching
in transplantation. To conduct this study, we reviewed the transplant literature to find all proposed
genetic matching methods currently available. In addition, we also researched various distance
metrics and measures to define our own single SNP matching scores that quantify the differences
between D/R genomes. To test the statistical power and estimate type I error values of these
matching score methods, we perform joint testing of each single variant score together with the
recipient variant. If an association is found using the joint testing approach, we then conduct
separate marginal tests to determine what is truly driving the association. Power of these joint
and marginal tests is assessed both analytically and using simulations. We also utilize liver
transplant data to demonstrate how these scores can be used with time-to-event data.
In Chapter 3 we focus on extending the single variant methods to create multi-marker genetic
matching scores. Single variant approaches often suffer from lack of statistical power, due to the
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number of tests that must be accounted for when testing for association with an entire genome.
By grouping variants into gene regions prior to testing, the number of tests is drastically
decreased, which can help increase statistical power to find true associations. Due to the high
amount of correlation between genetic variants, it is also difficult to determine if an associated
variant is truly associated with a disease phenotype or if it is correlated with the variant that is
associated. Grouping variants helps to deal with short distance correlation and can make it easier
to obtain reproducible results from multiple studies. To jointly test for association of a multimarker genetic matching score and recipient genotype variants, we construct a Joint Score Test
(JST). Our proposed test statistic is built upon marginal likelihood scores for testing multiple
single-nucleotide polymorphism (SNP) effects and a gene-based matching score effect. We use
only the most informative linear combinations of single SNP recipient marginal likelihood scores
to increase the statistical power of JST. Our method also allows for flexible covariate adjustment,
which is important in transplantation studies since we want to account for the various clinical
factors also considered in D/R matching. We utilize statistical simulations to test the power and
type I error estimates of our JST and compare it with other common multi-marker genetic
methods. JST is also used to analyze data from kidney transplant studies to determine if any
gene regions may be associated with acute rejection.
In Chapter 4 we focus on the task of locating genomic regions where D/R matching may improve
transplant outcomes while accounting for potentially high-dimensional recipient SNP effects. For
this work, we select four high-dimensional analysis methods and compare their estimated type I
error and power levels for testing for association with a gene-based matching score with a
rigorous simulation study. As part of this study, we account for the possibility that many recipient
SNPs are being accounted for by the model, with an assumption that the effects of these SNPs
are relatively sparse.
In the final chapter we summarize what we learned throughout these studies and discuss
potential avenues to explore in future work.
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CHAPTER 2

JOINT TESTING OF DONOR AND RECIPIENT GENETIC MATCHING SCORES AND
RECIPIENT GENOTYPE HAS ROBUST POWER FOR FINDING GENES
ASSOCIATED WITH TRANSPLANT OUTCOMES

2.1 Introduction
In the field of transplantation, a major focus is matching potential donors to recipients to have a
high probability of successful transplant outcome. Currently, there are a wide range of clinical
features that are considered when matching a transplant recipient to a donor. These range from
donor aspects, such as age, sex, and whether the donor is living or deceased, to recipient
aspects, such as age and sex (Reddy, Varghese, Venkataraman, & Rela, 2013). Genetic
matching for transplantation, when the number of similar alleles in donor and recipient genotypes
that modify transplant outcome is maximized, has also been performed for some organ types but
has mainly focused on the HLA regions of the genome since this region is responsible for
immune responses that can lead to transplant rejection (Lim, Wong, Heidt, and Class, 2018;
Sypek, Kausman, Holt, and Hughes, 2018). Some studies have shown that there are gene
regions outside of the major histocompatibility complex that are genetic modifiers for transplant
outcomes (Steers et al., 2019, McCarroll et al., 2009, Grafft et al., 2009, Yang, & Sarwal, 2017;
Almoguera, Shaked, & Keating, 2014).
Genetic association studies for transplant outcomes tend to look at the recipient genome only
(Dorr et al., 2018). Individual recipient SNPs have been found to be associated with acute
rejection outcomes for kidney, liver, and heart transplants (Green et al., 2017; Morris et al., 2015;
Almoguera, Shaked, & Keating, 2014). Recipient’s genes have also been found to affect
pharmacogenetic outcomes, such as immunosuppressant concentration in transplant recipients
(Dorr et al., 2018; Oetting et al., 2016; Almoguera, Shaked, & Keating, 2014). Multiple studies
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have examined how differences in transplant outcomes that seem to be based on self-reported
race may be because of underlying genetic differences between different ethnic groups (Green et
al., 2017; Morris et al., 2015). Fewer studies have been carried out looking at the association
between the donor genome and transplant outcomes, but polymorphisms in donor APOL1 and
TLR4 genes have been found to be significantly associated with negative transplant outcomes in
the kidney and liver respectively (Julian et al., 2017; Oetting et al., 2012; Dorr et al., 2018). The
biological mechanisms behind genetic matching in transplant studies remain elusive. One
common hypothesis is that the recipient mounts an immune response after recognizing the donor
organ as non-self. There is also the potential for regulatory pathways to become disrupted if
SNPs located in non-coding gene regions differ between donors and recipients. Genetic
differences have also been known to affect metabolism of immunosuppressant drugs (Yang, &
Sarwal, 2017). In addition, many studies have found discrepancies between transplant outcomes
for recipients of different races, especially if donor and recipient are of different races (Morris et
al., 2015; Pang et al., 2009; Nair and Thuluvath, 2001; Nair, Eustace, and Thuluvath, 2002;
Zhang, 2017; Saxena et al., 2012). It has been conjectured that these discrepancies may have
been caused by genetic differences between donor and recipient (Julian et al., 2017). To work
towards understanding biological mechanisms behind transplantation success and failure, it may
be useful to quantify the genetic differences between transplant donors and recipients beyond
one of their genomes.
More recently, researchers have started to examine the joint effect of donor and recipient
genomes by looking at genetic mismatch between the two. Using an Allogenomics Mismatch
Score (AMS) method that generates a difference score between transplant donor and recipient
genomic markers, exonic SNPs coding for transmembrane proteins were found to be associated
with long term kidney graft function (Mesnard et al., 2016). Donor/recipient (D/R) pairs with a
higher number of non-HLA mismatched variants prior to kidney transplant were found to have an
increased risk of antibody mediated rejection after transplant (Pineda et al., 2017). A method
similar to the AMS, which we refer to as the binary mismatch score, was used to examine
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genome-wide mismatches in non-synonymous SNPs (nsSNPs) found in transmembrane and
secreted proteins (Reindl-Schwaighofer et al., 2019). This study found that the number of nsSNP
mismatches was independently associated with graft loss in a multivariate model that adjusted for
HLA eplet mismatch (Reindl-Schwaighofer et al., 2019). Under a genomic-collision model,
defined as a scenario in which a recipient who is homozygous for a deletion-tagging allele was
paired with a non-homozygous donor (Steers et al., 2019), a single recipient SNP in the LIMS1
locus was confirmed to have association with kidney graft rejection. These works suggest that
paired analyses of donor-recipient genomes may shed new light on biological mechanisms
underlying transplant outcomes. To date, however, there has not been systematic assessment on
the power of the AMS, and binary mismatch scores, and it is of interest to understand the
relationship among these scores. The AMS and binary mismatch scores focus on one specific
biological mechanism where the recipient would create donor-specific antibodies that would
initiate an immune response towards the graft. It is of interest to gain insight into alternative
biological mechanisms using alternative paired scores.
In this chapter, we assess and compare the three methods discussed above and propose a new
method based on the degree of identity-by-state (IBS) mismatch between the donor and recipient
genomes. The remainder of the chapter is formatted as follows. In section 2.2, we present the
four scoring methods and discuss how these scores are related. Section 2.3 describes results of
extensive simulation studies comparing the performance of the four scores, as well as an analysis
of liver transplant genetic data using these methods. Finally, in section 2.4 we will discuss the
benefits and potential limitations of these methods.

2.2 Methods
Four different methods were utilized to calculate difference scores between transplant donors and
recipients, which were then used in analysis to determine if these scores were associated with
differential transplant outcomes.
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2.2.1 Notation
We define

and

as the number of minor alleles (0, 1, 2) present at SNP for the donor and

the recipient, respectively. For our models, we consider a general regression setting. Depending
on the phenotype variables available for analysis, models can either be in the form of generalized
linear models for continuous or categorical outcomes,

, or Cox proportional hazards models, for

a time to event outcome. Our generalized linear model is of the form

where g() is the link function,

, and

are covariate values for

recipient i with regression coefficients
genotype with coefficient

and

. We let

correspond to the recipient

corresponds to one of the matching scores that will be

introduced below with coefficient . We let

, where n corresponds to the total number

of donor/recipient pairs in the study.
For time to event outcomes, we use the Cox proportional hazards model

to assess whether our distance measures are associated with the hazard of transplant outcome.
In the above formula,

refers to the hazard function at time point t,

is the

baseline hazard function, and all other notation is the same as was discussed for the generalized
linear model. We wish to test the null hypothesis of null genetic matching effect:
,
or jointly test the global null hypotheses of null genetic effect:

.

7

2.2.2 IBS Mismatch Score
The proposed method, the IBS mismatch score, is based on the degree of identity-by-state (IBS)
between pairs of individuals. Identity-by-state refers to when two individuals share the same
alleles at a genomic locus. This sharing may be because of a recent common ancestor between
the two individuals, in which case the region would be considered identical-by-descent, or
because of the alleles matching by chance. In either case, the individuals have some number of
alleles in common. The IBS mismatch score is calculated as

,
where

and

are defined above. The

() function is a measure of the dissimilarity

between the donor and recipient genomes at a particular SNP, and is defined as

assuming SNPs are diallelic. A version of this measure was used as a kernel function in a leastsquares kernel machine approach to test multiple genetic markers in association with quantitative
traits (Kwee et al., 2008). Their kernel was used to produce a scalar measure of similarity
between multiple SNPs in a genetic region, whereas our score focuses on a single SNP (Kwee et
al., 2008).

2.2.3 Incompatibility Score
The IBS score quantifies similarity between the donor and recipient genomes, but it is possible
that a difference that exists between the two genomes may matter more than the degree of the
difference. This concept motivates a second method that we call “the incompatibility score”. This
score is defined as

where the incompatibility function is defined as
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A score similar to this has been considered for maternal and fetal genotypes in relation to the risk
of pre-eclampsia (PE; Parimi et al, 2008). While none of the SNPs tested were significantly
associated with PE after correcting for multiple testing, the authors were able to find SNPs from
three candidate genes such that their incompatibility effect was nominally associated with PE.
Interestingly, the incompatibility of one of these SNPs showed a protective effect, suggesting that
incompatibility between genomes does not necessarily lead to a worse outcome (Parimi et al,
2008). This score has also been utilized in kidney transplant, where both single SNP mismatches
and genome-wide mismatch were found to be associated with antibody-mediated rejection and Tcell mediated rejection (Pineda et al., 2017).

2.2.4 The Allogenomics Mismatch Score (AMS) and Binary Mismatch Score
The Allogenomics Mismatch Score (AMS) uses genomic markers to generate a difference score
between transplant donors and recipients (Mesnard et al., 2016). It is based on the allogenomics
concept, the hypothesis that looking at the difference between transplant donor and recipient
alleles in the coding regions of the genome can give insight into which amino acids coded by the
donor genome would present as non-self to the recipient immune system. The AMS was defined
as

,
where

refers to the genotype of recipient r at genomic site l,

donor d at site l, and

refers to the genotype of

is defined as

where a denotes alleles of a genotype. Essentially, the

function is equal to 0 if both the donor

genotype alleles are in the recipient genotype, is equal to 1 if the donor genotype contains an
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allele not present in the recipient genotype, and is equal to 2 if the donor genotype contains two
alleles not present in the recipient genotype. To compare this method to our scores, we will apply
the

function over both alleles at a SNP to obtain a mismatch score

The binary mismatch score was defined similarly to the AMS,

.
Instead of summing across the alleles in the genotype, however, this score assigned a 1 to
instances when the donor genotype had any alleles not present in the recipient genotype and a 0
otherwise (Reindl-Schwaighofer et al., 2019).

2.2.5 Comparison of Scores
The IBS mismatch score, incompatibility score, the AMS, and the binary mismatch score are
related to one another. This relationship can be seen clearly in Table 2.1, which gives the
possible score values for each method and the donor/recipient genotype pairs that result in each
score. The incompatibility score acts as a simplified version of the IBS mismatch score, collapsing
the IBS scores of one and two into a single score category. The AMS equals the IBS mismatch
score when the recipient genotype is homozygous but assigns a score of 0 when the recipient
genotype is heterozygous. The binary mismatch score resembles a simplified AMS score and
equals the incompatibility score when the recipient genotype is homozygous. Figure 2.1 shows
how the population frequency of each score changes across a range of minor allele frequencies,
assuming unrelated donor/recipient pairs and Hardy-Weinberg equilibrium (HWE). For the IBS
mismatch score, lower minor allele frequencies (MAFs) result in higher
increases,

and

increase while

incompatibility score and AMS follow the same trend, but
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. As MAF

decreases. The
,

and

always remain relatively small across the range of MAFs, which may lead to low
statistical power for association testing, unless the effect size is very large.
Table 2. 1: The possible score values for the IBS mismatch score ( ), incompatibility score
(
) the Allogenomics Mismatch Score (
) and the binary mismatch score (
) and the D/R
genotype pairs that result in these score values.
is donor genotype,
is recipient genotype.
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Figure 2. 1: Expected probabilities of different score values for the IBS Mismatch Score ( ), the
incompatibility Score (
), the Allogenomics Mismatch Score (
) and the binary mismatch
score (
) under different minor allele frequencies.

2.2.6 Joint Testing of β and γ
In the presence of donor-recipient matching effects, a standard association test between the
outcome and recipient genotype can be misleading. We will use an example below to
demonstrate how such tests can produce biased results. We therefore recommend a joint test of
recipient genotype and matching score as the first step to account for any donor-recipient
matching and recipient genetic effects.
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Consider a scenario where recipient and donor genotypes are related to a binary phenotype, ,
through the incompatibility score

:

where

. In this model, the donor-recipient

matching, not just the recipient genotype, is the risk factor for the outcome. For a standard
association test with recipient genotype, like in a recipient only GWAS, a model as below would
be considered:

where for simplicity, we adopt the dominant coding for

(0 for aa and 1 for Aa or AA). If we

assume that HWE holds for donors and recipients and that the phenotype is rare, the fitted odds
ratio,

, can be expressed as a function of the true odds ratio,
, and the minor allele frequency.

Figure 2.2 reveals a few insights into the relationship between fitted ORs and true ORs, with SNP
MAF ranging from 0.05 to 0.5. First, for all true ORs used, the fitted OR has the opposite effect
size. When the true odds ratio is less than 1 indicating a protective effect of incompatibility, for
example, the fitted odds ratio is always greater than 1 indicating an increased risk for recipient
genotype. Second, for the smallest MAFs, 0.05 and 0.1, the fitted odds ratio tends to be the
inverse of the true odds ratio. This is because

in these instances, which simplifies the
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above equation into

. Finally, the closer the true odds ratio is to 1, the smaller the

difference between the true and fitted OR.

Figure 2. 2: Minor allele frequency (MAF) versus true and fitted odds ratios (OR) calculated
using the empirical equation
. The horizontal line corresponds to an OR of 1.00. The blue points
correspond to the true OR and the red points correspond to the fitted OR.

If the IBS mismatch or the AMS score were considered instead of the incompatibility score, a
similar relationship between the fitted and true ORs would be found but the result would be
slightly more complicated because these scores are not binary. Similarly for the binary mismatch
score, which acts as a less restrictive incompatibility score by focusing only on alleles present in
the donor genotype that are not present in the recipient genotype.
On the other hand, we can consider an opposite situation in which the outcome is associated only
with recipient genotype, but we test for the matching score. Similar derivation will lead to the
same relationship (bias) between the fitted and true ORs. These results signal that caution must
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be used when performing association analyses when a donor-recipient matching effect is
possible. Wrongly specified models may lead to misleading association results, even giving an
opposite direction of effect. This misspecification cannot be easily avoided, however, since it is
not possible to know whether the recipient genotype or one of the matching scores is truly
associated with outcome phenotype before association testing is done. In light of these results, it
is of interest to first jointly test the association of both score and recipient genotype as a
screening test for association. The joint tests with significant results could then be followed by
testing the univariate models of score or genotype to determine which of the two is truly driving
the association. A similar two-stage method has been used in gene-environment interaction
testing where this method led to improved power for finding relevant associated genes (e.g., Dai
et al., 2012).

2.2.7 Simulations
Simulation studies were conducted to address three questions. First, we assess the type I error
rates for the different scores. Second, we compare the power of joint testing significance of
recipient genotype and score and univariate testing of only the score or genotype. Third, we
compare the univariate power between the different scores.

2.2.7.1 Generation of the Simulated Datasets

Separate datasets were created for 22 immune related genes previously found to be associated
with transplant outcomes (Table A.5). Phase 2 HapMap CEU genotypes, downloaded from the
PLINK website (Purcell et al., 2007), were subset into gene regions based on starting and ending
locations. Haplotype frequency data and SNP information was then extracted using Haploview
4.2 (Barrett et al., 2004) (Example: Table A.4). This data was then read into R (v 3.6.1; R Core
Team, 2018) and two haplotypes were sampled based on haplotype frequency under HardyWeinberg Equilibrium and paired up to generate genotype data. Genes ranged from having 2
SNPs (HMOX1, IFNL3) to 68 SNPs (CXCL12) with a median of 14 SNPs per gene. In total, 447
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SNPs were tested across the 22 genes. We considered a small, 500 donor/recipient (D/R) pairs,
and a large, 1000 D/R pairs, sample size.
The incidence of acute rejection for liver transplant has been reported to be between 10-40%. We
therefore chose to fix incidence rates at 15 and 30% for type I error and power analyses (Dogan
et al., 2018; Choudhary et al., 2017). Phenotypes were generated using the model

where

denotes the outcome phenotype of recipient i in a sample of N total donor/recipient pairs

and all other variables are defined earlier in the Methods section. We note that the model is
simplified slightly, where

in this case can correspond to either a single recipient genotype

SNP or one of the single SNP score values.
To determine the power of joint testing, we consider a true model where recipient and donor
genotypes are related to binary phenotype only through one of the scores

Of interest is whether jointly testing the significance of the recipient genotype SNP and the score
will tend to decrease the power to find the true association. We fit three separate models where
we included the single SNP scores only, the recipient genotype SNP only, or both the score and
the recipient genotype at the same SNP,

and

We then tested the power of rejecting the null hypotheses
two models as well as jointly testing the power of the hypothesis
third model. For these analyses,

or

, for the first
for the

was coded according to the additive model of inheritance (0
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for aa, 1 for Aa, 2 for AA). A similar analysis was also conducted where the true model was taken
to be

and all three models were once again fit and tested for power as was described above.
For type I error analysis, we used an effect size of

to generate data under the null model.

For power analyses, a range of OR parameters,
were used. In both cases

,

was calculated to ensure the incidence of outcome was either 15 or

30%. Logistic regression models were fit for each SNP of the forms described earlier. A total of
5000 simulations were conducted for each sample size.

2.2.8 Real Data Analysis

2.2.8.1 Sample Information

We utilized samples from four liver transplant studies which were conducted on behalf of the
international genetics & translational research in transplantation network (iGeneTRAiN). Most of
the donors were deceased at the time of transplant, and most donor and recipient pairs were
related. All transplants were conducted between 2000 and 2014. The average age of recipient
was around 55 and all four studies had around 25% female recipients. All studies also had a
majority of Caucasian recipients (73 to 92%). The incidence of acute rejection (AR) outcome
ranged from 10-40% in the four studies. In total the data contained information on 1966
donor/recipient pairs of varying ethnicities. Analyses were restricted to a subset of Caucasian
only recipients, 1418 pairs, to reduce the chance of false-positive findings related to differences in
genetic ethnicity. All data sets were genotyped using the Axiom Tx SNP GWAS array, a
genotyping chip of approximately 782,000 SNPs that has been specially curated to include
variants of importance to transplant, including variants involved in immune response. All the data
was imputed using the 1000 Genomes v3 as reference (Keating et al., 2015; Li et al., 2015). After
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imputation, SNPs were removed from analysis if they had MAF smaller than 0.05, did not follow
Hardy-Weinberg equilibrium, or had more than 1% missingness.
The analysis of the whole genome is ongoing. To demonstrate our methods, we gained access to
data for 167 SNPs located in 20 immune related genes that had previously been found
associated with liver transplant outcomes in the literature (Almoguera, Shaked, & Keating, 2014).
For each of the gene regions, SNPs were pulled from PLINK binary files using PLINK 1.7 (Purcell
et al., 2007). Gene regions were subset based on the starting location and ending location of
each gene from the Genome Reference Consortium Human Build 37 (hg19).

2.2.8.2 Statistical Analysis

The IBS mismatch score, incompatibility score, the AMS and the binary mismatch score were
calculated for each SNP in each gene region using the methods described earlier.
Separate Cox proportional hazards models were created for each scoring method to assess
association between each SNP with time to acute rejection after liver transplant. Models were
adjusted for the covariates of recipient age, recipient gender, study, categorized year of
transplant and the first 3 principal components from the recipient genotype data. If a SNP was
found to be significantly associated with AR during joint analysis, then separate univariate models
were created that included recipient genotype and score alone. All analyses were conducted
using R (v 3.6.1; R Core Team, 2018). Significance was determined based on an alpha of 0.05,
and Bonferroni correction was also utilized to account for multiple testing.

2.3 Results
2.3.1 Simulation Results

2.3.1.1 Type I Error Analysis

Type I error analysis gave no indication of inflated false positive rates for any of the simulation
models we specified. More details can be seen in Appendix A.
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2.3.1.2 Joint Power Analysis

Figure 2.3 shows the results of power analysis for both the joint modeling and univariate modeling
under the true models of IBS mismatch score or recipient genotype SNP being associated with
outcome. Both analyses show that jointly testing the significance of the recipient genotype and
the score variables has only slightly lower power than the univariate testing of the correct model
for all SNP MAFs. Importantly, this relationship occurs despite the fact that the incorrect
univariate model has low power to detect an association across all MAFs.

Figure 2. 3: Plots of estimated statistical power versus SNP minor allele frequency for joint
modeling both the recipient genotype and the IBS mismatch score. Results are shown for a true
odds ratio of 1.45 and an outcome prevalence of 15%. From left to right, the true model is that
IBS mismatch score is associated with the outcome and that recipient genotype is associated
with the outcome.

This trend can be seen for all four scores (Figure 2.4). In general, MAF does not appear to have
an impact on power. Comparing the power levels for the scores, it appears that the AMS has the
highest power overall. The binary mismatch score has the lowest power overall, although its
power is comparable to the incompatibility score. The IBS mismatch score has slightly higher
power than the incompatibility score and has similar or slightly lower power compared to the
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AMS. In all cases, the relatively high power levels do not seem to be because of inflated type I
error rates (Figure A.1). Overall, these simulations confirm that joint testing is almost as powerful
as univariate testing for all SNP MAFs and for all scores.

2.3.1.3 Marginal Power Analysis

Figure 2.5 shows the results for univariate power analyses, comparing the four scores and the
recipient genotype. We see that the IBS mismatch score, the recipient genotype, and the AMS
have comparable power across all SNP MAFs. The incompatibility score and binary mismatch
score have lower power than the other scores for all MAFs. When the IBS mismatch score is the
true model, the incompatibility score has comparable power to the true model and vice versa.
This is not surprising because of the relationship between these two scores. By comparing the
average estimated ORs for each fitted model, we are better able to quantify the bias of the
misspecified models (Table A.1). When the incompatibility score is used to create the
phenotypes, for example, the true model results in estimated ORs around 1.45 (1.43-1.46), while
the misspecified models looking at association of the IBS mismatch score with outcome results in
estimated ORs ranging from 1.28 to 1.41, the misspecified models where AMS is assumed to be
associated with outcome estimate ORs ranging from 1.14 to 1.34, and the misspecified models
using the binary mismatch score result in OR estimates ranging from 1.23 to 1.37. In all cases,
fitting an incorrect score tends to result in loss of power, as expected, and the loss can be severe.
Therefore, if there is no prior hypothesis of which score is best to fit it may be beneficial to fit all
four scores although this would lead to a higher amount of multiple testing.
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Figure 2. 4: Plots of estimated statistical power versus SNP minor allele frequency for joint
modeling both the recipient genotype and each of the four scores. Results are shown for a true
odds ratio of 1.45 and an incidence of outcome of 15%. From top to bottom, and left to right, the
true models are that IBS mismatch score is associated with the outcome, that incompatibility
score is associated with the outcome, that the Allogenomics Mismatch Score (AMS) is
associated with the outcome, and that binary mismatch score is associated with outcome.
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Figure 2. 5: Estimated power level versus SNP MAF for power analyses. Results shown are for
an incidence of outcome of 15% and a true odds ratio value of 1.45. For each plot, a different
single SNP covariate value was used to generate the true phenotype values. From top to
bottom, and left to right, the covariate used to generate phenotypes is recipient genotype, IBS
mismatch score, incompatibility score, Allogenomics Mismatch Score (AMS), and binary
mismatch score.
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2.3.2 Real Data Analysis Results
Table 2.2 shows the hazard ratios and uncorrected p-values for the top associated SNP in each
gene along with the score that was significantly associated with outcome for the joint model and
the results of univariate analyses. For seven genes, joint analyses were able to find SNPs
significantly associated with outcome. Univariate analyses were then able to determine whether
the recipient genotype or the score was driving the association. When recipient genotype was
associated with outcome, such as for SNPs rs4363 (ACE), rs2640539 (AGTR1), rs2856758
(CCR5), and rs800323 (CXCL12), joint analyses of multiple scores tended to produce significant
associations. In some instances, both the score and recipient genotype remained associated in
univariate analyses, for example both the recipient genotype and the binary mismatch score were
found to be associated with AR for SNP rs4363 (ACE). In cases when the score was significantly
associated both in joint and univariate analysis, there is little change between the joint and
univariate hazard ratio and confidence interval, as seen for both rs3024613 (IL4R) and
rs11777928 (TNFRSF10A), but at times the univariate p-values are smaller than the joint testing
p-values.
Table 2. 2: Hazard ratios and 95% confidence intervals for the top SNP in each gene region that
was significantly associated with transplant outcome for at least 1 score. Results are based on
Caucasian recipients only. Multivariate hazard ratios and joint p-values are shown, as well as
univariate hazard ratios and p-values for score or genotype that remained significant in the
univariate model. Bold results are significant using alpha of 0.05, †Results reach significance
after Bonferroni correction.

RSID (Gene)

Score used in
Joint Model

IBS
Mismatch
Score

rs4363
(ACE)

Incompatibility
Score

Allogenomics
Mismatch
Score

Joint Analysis
Univar.
Joint Analysis
R Genotype Joint P- Genotype/Score in
Analysis
Univariate
Score Hazard
Hazard Ratio Value Univariate Model Hazard Ratio P-Value
Ratio (95% CI)
(95% CI)
(95% CI)

1.00

1.29
0.03

(0.81, 1.23)

(1.07, 1.57)

0.94

1.29
0.03

(0.72, 1.23)

(1.06, 1.56)

0.89

1.28
0.02

(0.72, 1.10)

IBS
Mismatch
Score
Incompatibility
Score
Allogenomics
Mismatch
Score

0.97
0.76
(0.79, 1.19)
0.92
0.55
(0.71, 1.20)
0.86
0.17
(0.70, 1.07)

(1.05, 1.56)
Binary
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0.72

0.03

Binary
Mismatch
Score

IBS
Mismatch
Score
rs2640539
(AGTR1)
Allogenomics
Mismatch
Score

IBS
Mismatch
Score
Incompatibility
Score
rs2856758
(CCR5)

Allogenomics
Mismatch
Score

Binary
Mismatch
Score

IBS
Mismatch
Score
Incompatibility
Score
rs1436926
(CXCL12)

Allogenomics
Mismatch
Score

Binary
Mismatch
Score
IBS
Mismatch
Score
rs3024613
(IL4R)

Incompatibility
Score

Allogenomics
Mismatch

0.75

Mismatch
Score

1.29
4.74E-03†

(0.55, 1.00)
1.40

(1.05, 1.58)
1.44
0.01

(1.10, 1.80)

(1.10, 1.88)

1.36

1.25

(1.09, 1.71)

(0.99, 1.59)

0.84

1.24
0.04

(0.63, 1.12)

(0.89, 1.74)

0.82

1.25
0.04

(0.60, 1.12)

(0.90, 1.74)

0.77

1.40
0.02

(0.57, 1.04)

(1.04, 1.90)

0.71

1.44

(0.50, 1.02)

(1.06, 1.94)

1.47

1.53
2.56E-03

(1.12, 1.92)

(1.16, 2.03)

1.45

1.49
0.01

(1.08, 1.95)

(1.12, 1.97)

1.45

1.30
2.39E-03

(1.13, 1.87)

1.25

(1.13, 2.08)

(0.97, 1.61)
0.98
0.01

(1.12, 1.70)

(0.81, 1.19)

1.49

0.98
0.02

1.29

(0.97, 1.51)

Recipient
Genotype
IBS
Mismatch
Score
Incompatibility
Score
Allogenomics
Mismatch
Score

Recipient
Genotype
IBS
Mismatch
Score
Incompatibility
Score
Allogenomics
Mismatch
Score
Binary
Mismatch
Score

3.27E-03

(1.11, 2.01)

IBS
Mismatch
Score

0.01
1.21
0.10
1.33
0.01
(1.07, 1.66)
1.24
0.09
(0.97, 1.59)
0.76
0.03
(0.59, 0.98)
0.74
0.03
(0.56, 0.98)
0.79
0.11
(0.58, 1.06)
0.75
0.11
(0.53, 1.07)
1.38
0.03
(1.02, 1.85)
1.23
0.10
(0.96, 1.58)
1.24
0.13
(0.94, 1.63)
1.43
3.86E-03
(1.12, 1.83)

(1.01, 1.67)

1.53

1.38

(1.07, 1.56)

Binary
Mismatch
Score
0.01

1.29

Recipient
Genotype

Allogenomics
Mismatch
Score
7.63E-03

(0.54, 0.97)

Recipient
Genotype

1.59
2.76E-03
(1.17, 2.15)
1.31
0.04
(1.01, 1.71)

IBS
Mismatch
Score

(1.12, 1.71)

Incompatibility
Score

(1.11, 2.01)

1.38
2.57E-03
1.49
0.01

(0.80, 1.19)

0.98
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0.04

Allogenomics
Mismatch
Score

1.29
0.01
(1.07, 1.56)

Score
(1.07, 1.56)

0.80
rs12443062
(TNFAIP8L3)

0.03
(0.60, 1.06)

rs11777928
(TNFRSF10A)

Allogenomics
Mismatch
Score

Binary
Mismatch
Score

Incompatibility
Score

1.20

Incompatibility
Score

IBS
Mismatch
Score

Recipient
Genotype

(0.81, 1.18)

1.37

Recipient
Genotype

(0.93, 1.56)
1.05
0.02

(1.10, 1.70)

(0.85, 1.29)

1.35

0.99
0.01

(1.11, 1.63)

(0.82, 1.20)

1.49

0.95

(1.13, 1.96)

(0.79, 1.14)

IBS
Mismatch
Score
Allogenomics
Mismatch
Score
Binary
Mismatch
Score

0.02

Recipient
Genotype

0. 96
0.68
(0.78, 1.17)
0.74
0.03
(0.57, 0.97)
1.29
0.04
(1.01, 1.65)
1.34

4.49E-03†

(1.10, 1.65)
1.35

1.90E-03†

(1.12, 1.63)
1.49

4.65E-03†

(1.13, 1.96)
0.95
0.61
(0.78, 1.16)

2.4 Discussion
We studied four methods for use in association analysis of transplant outcomes. These methods,
the IBS mismatch score, the incompatibility score, the AMS score, and the binary mismatch
score, are genetic matching score methods designed specifically for use with transplant data. We
showed that while these four scores are related, they have different probability distributions, and it
is also likely that they are measuring different aspects of donor/recipient genotype matching. We
demonstrated that model misspecification can be extremely detrimental to analysis results. In all
cases, regardless of MAF or true OR value, the fitted OR was always of an opposite effect
direction as compared to the true OR. These results emphasize the need to be mindful of
potential model misspecification and led us to consider joint testing of both score and recipient
genotype as the method of choice for screening individual SNPs.
Our simulation studies showed that jointly testing a model containing recipient genotype SNP and
matching score was almost equally as powerful as marginally testing the true model. Similar
results have been demonstrated before in the context of gene-environment interaction studies.
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Kraft et al. (2007) showed that a joint two degree of freedom test had comparable power to
marginal and interaction-based tests. By jointly testing, we can maintain good power levels even
under a misspecified model whereas a misspecified marginal model loses power considerably.
After joint testing is complete, those SNPs that were found to be significant using this method can
be tested using univariate models to determine if the recipient genotype or the score or both are
driving the association with outcome.
Our analysis of liver transplant data led to identification of seven genes having at least one SNP
significantly associated with time to acute rejection. Marginal testing of these top SNPs revealed
whether the score or recipient genotype was driving the associations. In cases where recipient
genotype SNP was associated with acute rejection outcome, multiple scores showed significance
in joint testing and often the confidence intervals for the score hazard ratios crossed 1. When
score was significantly associated with outcome, the hazard ratio and confidence interval remain
relatively constant between joint and univariate testing. Donor genotype was also considered in
our univariate analyses, but the top SNPs were not significantly associated with outcome.
Significant SNPs are noted in the supplementary tables (Tables A.2 and A.3). We note that when
a genetic matching score was marginally associated with the probability of acute rejection, but the
recipient or donor genotype SNP was not, the hazard ratios of the recipient genotype model and
the donor genotype model were not close to being significant. This could mean that the scores
are picking up on the difference between the donor and recipient genotypes and are not simply
acting as a stand-in for one of these values. In addition, LD analysis conducted using HaploReg
(v4.1, Ward and Kellis, 2011) showed that in some cases when multiple SNPs in a gene region
were marginally associated with acute rejection probability, there were multiple independent
associations.
These associated SNPs should be validated in independent studies. Evidence from previous
transplant association studies suggests that the genes ACE, IL4R, and AGTR1 were implicated in
acute rejection, and SNPs from ACE, including our top SNP rs4363, were found to be associated
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with sudden cardiac death in kidney transplant (Moe et al. 2019). Additionally, gene expression
studies found that expression levels of AGTR1 tended to be increased for heart transplant
recipients with recurrent rejection episodes, and expression levels of IL4R were increased in
natural killer cells after kidney transplant (Yamani et al. 2006, Zhu et al. 2018). While these genes
were not directly implicated in liver transplant outcomes, the fact that they were found to be
significant in other transplant scenarios is encouraging.
Earlier we discussed how these matching scores could be used to help suggest SNPs of interest
that may modify transplant outcome. In the case of our real data analyses, we specifically looked
at time to first acute rejection, which occurs when the recipient mounts an immune response
against the donor organ. Based on our results, some hypotheses of acute rejection mechanisms
are possible. A significant SNP was present in the gene CCR5, which is involved in sending
various immune cells toward sites of inflammation (Hütter, 2011; Ajuebor, Carey, & Swain, 2006).
Results showed that an increase in mismatch score for both the incompatibility score and the IBS
mismatch score were associated with decreased odds of acute rejection. It may be the case that
mismatch in this gene causes less transcription of the CCR5 protein and in turn leads to less
receptors available for binding and instructing other immune cells which could lead to less
inflammation and a less acute immune response in the donated liver.
Our methods do have limitations. For real data analyses, we were only able to test our methods
on liver transplant data. These methods can be applied to any organ transplant, but it would have
been helpful to be able to demonstrate their usefulness for at least one other organ type. In
addition, we focused on immune related genes for our initial testing, but it would be interesting to
test other genetic regions as well. For our simulation studies, we considered unrelated pairs of
donors and recipients as we sampled existing haplotypes to preserve LD among SNPs. These
results are also applicable to the related donor and recipient pairs. Future work will consider the
degree of relatedness of the matched pairs in association with successful transplant outcomes.
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In summary, these four genetic matching scores are powerful tools for future analysis of
transplant genetic data. Use of these scores in future association analyses may lead to further
understanding of the biology behind acute rejection, and other transplant outcomes, which could
lead to the prevention of these negative outcomes for future transplants.
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CHAPTER 3

A MULTI-MARKER TEST FOR ANALYZING PAIRED GENETIC DATA IN
TRANSPLANTATION

3.1 Introduction
Transplant matching usually focuses on non-genetic factors related to the donor, the recipient, or
the graft itself, such as recipient age, donor sex, or organ size. Genetic matching in transplant
has been limited to the human leukocyte antigen (HLA) region of the genome in the past, as this
region codes for immune related genes that may lead to the recipient recognizing the allograft as
non-self and mounting an immune response against it (Hernandez-Fuentes et al., 2018; Reddy et
al., 2013). Although HLA matching reduces the risk of allograft rejection, it is not enough to
prevent allograft rejection, even in the case of transplant between HLA-identical siblings (Zanoni
& Kiryluk, 2020; Grafft et al., 2010). More recent transplant genetic studies have identified gene
regions outside of the HLA region that may act as genetic modifiers for transplant outcomes
(Almoguera et al., 2014; Yang & Sarwal, 2017; Reindl-Schwaighofer et al., 2020; Marin et al.,
2020; Steers et al., 2019; Farouk et al., 2020). These so-called minor histocompatibility antigens
may be important regions of interest to examine further to improve transplant outcomes.
Several studies have found evidence suggesting that donor and recipient genetic mismatch in
these non-HLA regions could impact transplant outcomes. Zhang et al. (2020) showed that nonHLA donor/recipient (D/R) genetic differences were significantly associated with long-term graft
survival in kidney transplant. Pineda et al. (2017) found a significantly increased number of D/R
mismatched variants in the group of kidney transplant recipients with antibody-mediated rejection
(AMR) compared to the group with no rejection, and they were able to identify 16 gene regions
with multiple SNPs associated with AMR. Steers et al. (2019) utilized a genomic-collision model,
in which a recipient who is homozygous for a deletion tagging allele obtains a transplant from a
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non-homozygous donor and were able to find a single polymorphism located in the LIMS1 locus
with an increased hazard for rejection for D/R pairs with the collision genotype. In addition,
previous work on single nucleotide polymorphism (SNP) matching in transplant found that utilizing
D/R matching scores in association analyses led to discovery of SNPs potentially associated with
acute rejection after liver transplant. Joint testing of these scores with the recipient genotype also
suggested that the scores were measuring some aspect other than the combination of the
recipient and donor genotype, since there were cases where the score was associated with
transplant outcome, but the recipient and donor genotypes were not (Arthur et al., 2020). To
improve power, increase interpretability and reproducibility of association signals, and facilitate
follow-up functional studies, it is of interest to extend these single SNP methods to a multi-marker
framework.
Many multi-marker methods have been proposed in the literature for assessing the association of
multiple genetic markers within a gene region. Depending on how association information for
individual markers is aggregated, they can largely be classified into three groups. In the first
group, each test is based on combining p-values from tests of individual markers (Chen et al.,
2012; Mishra & Macgregor, 2015; Li et al., 2011). Members in the second group can be seen as
some quadratic form that combines statistics for testing marginal associations with each marker
(Pan 2011). Well-known examples include Hotelling’s T2 statistic (Fan & Knapp, 2003), genomicdistance based regression (Wessel & Schork, 2006), variance component (VC) or kernel machine
regression based tests (Tzeng & Zhang 2007; Pan 2009; Wu et al., 2010; Wu et al., 2011), the
use of weighted genetic risk scores (Li et al., 2009; Iribarren et al., 2018), and the C-alpha test
(Neale et al., 2011). These tests have also been extended using the framework of functional or
mixed effects models (Chiu et al., 2019; Chen et al., 2019; Fan et al., 2013). In the third group,
each test assesses associations between the phenotype variable and some form of aggregated
genotype data. For example, the principal component regression (PCR) method (Gauderman et
al. 2007; Wang & Abbot 2008; Chen & Qin, 2010; de Leeuw et al., 2015) tests the significance of
top principal components of centered multi-marker genotype data, and Wang and Elston (2007)
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test similarly collapsed variables obtained via Fourier transformations. Similarly to tests in the
second group, tests in this group have been built upon using functional data analysis methods
(Luo, Boerwinkle, & Xiong, 2011; Luo, Zhu, & Xiong, 2013). PCR and VC methods have been
shown to generally have competitive statistical power (Ballard et al., 2010; Pan 2011; Liu,
Barnett, & Lin 2020). The connections among some of these methods have been studied in the
literature (Bacanu 2012; Schaid 2010).
Only a few multi-marker D/R matching scores have been utilized for association analysis of
transplant genetics data. The allogenomics mismatch score (AMS) is based on the hypothesis
that observing the coding regions of both the recipient and donor genomes can help identify the
number of potentially incompatible amino acids between the pair (Mesnard et al, 2016). The AMS
is defined as the sum of amino acid mismatch contributions across all SNPs in the exome. A
negative linear association was observed between the AMS and estimated glomerular filtration
rate at 36 months post-transplant, suggesting that the AMS may be correlated with long term
kidney graft function (Mesnard et al., 2016). A second method defined variant mismatch as any
allele difference between the paired recipient and donor genomes (Pineda et al., 2017). This
study found that the total number of D/R variant mismatches prior to transplant was significantly
higher in the recipient group that developed antibody-mediated rejection versus the group with no
rejection. The final method defined SNP mismatch as the donor carrying an allele not present in
the recipient genome. These individual mismatches were then summed over all non-synonymous
SNPs (nsSNPs) in the genome. After fitting a multivariate model that adjusted for HLA eplet
mismatch, the degree of nsSNP mismatch was independently associated with graft loss (ReindlSchwaighofer et al., 2019). While these methods were able to find some association between
genome-wide mismatch and transplant outcomes, the results are difficult to interpret due to the
scores spanning the entire genome. By extending existing gene-based test ideas to use both the
recipient and donor genotype information, we have the potential to increase the power and
interpretability over single SNP and whole genome-wide scoring methods.
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Here we propose a new method called the “Joint Score Test (JST)”. JST is built upon marginal
likelihood scores for testing multiple SNP effects and a gene-based D/R matching score. JST
uses only the most informative linear combinations of single recipient SNP marginal likelihood
scores to allow for an increase in statistical power. JST also allows for flexible adjustment for
covariates and therefore it can maintain nominal type-I error rates in the presence of population
stratification.
We organize this chapter as follows. In section 3.2, we discuss the underlying model and the
construction of JST. Then in section 3.3 we present the results of extensive simulation studies. In
section 3.4, we utilize JST in an association analysis of kidney transplant data. Finally, we
discuss the benefits and potential limitations of the method.

3.2 Methods
JST jointly tests whether recipient genotype SNPs or a gene-based D/R matching score are
associated with the transplant phenotype of interest.

3.2.1 Notation
Suppose that genotype data for m SNPs in a genomic region of interest are available for n
transplant D/R pairs. Let

and

be the numerical coding of the genotype of the jth marker for

the ith recipient or donor, respectively

, which can be the number of

minor alleles or another numerical coding, and let

be the kth covariate of D/R pair i. We

consider a regression setting with continuous or categorical outcomes, Yi, and our generalized
linear model (GLM) is of the form

where g() is the link function,

, and

is the vector of K covariates for

D/R pair i with regression coefficients

Let

genotype vector of m SNPs for recipient i with regression coefficients

32

denote the
and let

denote the single gene-based genetic matching score value for D/R pair i with regression
coefficient . Note that

may include principal components (PCs) for describing population

substrata. We are interested in jointly testing the null hypotheses

.
3.2.2 Gene-based Scores
In general, each gene-based score can be written in the form

where

represents a function defining a distance between the donor and recipient

genotypes. We emphasize that the donor and recipient SNPs used in the distance calculations
are not necessarily the same as those present in the recipient genotype main effects vector

,

and thus can be greater or fewer in number. We will focus on four different single SNP distance
functions.

3.2.3 Single SNP Distance Scores
The first score, the IBS mismatch distance function, is defined as

assuming diallelic SNPs. This function is based on the degree of identity-by-state between the
donor and recipient genotypes, measuring the number of alleles the pair shares at a SNP. IBS
has previously been used as a kernel function in the sequence kernel association test (Wu et al.,
2011) and in a kernel machine approach to test multiple genetic markers in association with
quantitative traits (Kwee et al., 2008).
The second score considered, the incompatibility distance function, is calculated as
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This distance metric has been utilized in a kidney transplant study, where single SNP
incompatibility and a genome-wide sum of this measure were found to be associated with
antibody-mediated rejection (Pineda et al., 2017). In addition, a similar score was utilized in
mother/child pairs in a genetic study of pre-eclampsia (PE), where they found SNPs from three
candidate gene regions to be nominally associated with PE (Parimi et al, 2008).
The third score, the Allogenomics Mismatch Score (AMS) distance function, is defined as

where a denotes alleles of a genotype (Mesnard et al., 2016). The underlying hypothesis of this
method states that examining the difference between transplant donor and recipient alleles in
coding regions of the genome can give insight into which amino acids coded by the donor would
present as non-self to the recipient immune system, potentially leading to allograft damage.
The fourth score, the binary mismatch score, is based off a simplification of the AMS which
assigned a score of 1 for all SNPs where the donor genotype contained an allele that was not
present in the recipient genotype and a score of 0 otherwise (Reindl-Schwaighofer, 2019). The
single SNP distance function can be defined as

.
3.2.4 A New Multi-Marker Test Statistic for Paired Transplant Data
Let

denote the predicted probability of

model
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based on the null

Here

and

are the maximum likelihood estimates of

and . Additionally, we let

denote

the fitted value for the jth SNP genotype for recipient i from a weighted linear regression model
and let

denote the fitted value for the gene-based genetic

matching score of D/R pair i from a weighted linear regression model
. In both cases, the weights are

for recipient i or D/R pair

i. As derived in Appendix B, the likelihood score for testing the marginal association with the jth
recipient SNP is equivalent to

.
Similarly, the likelihood score for testing the marginal association with the gene-based D/R SNP
genetic matching score is equivalent to

.
Denote the vector of scores for all m recipient genotype SNPs and the gene-based genetic
matching score as

,

, let

and

. Then U can

be written into the matrix form,

,

which is asymptotically distributed as a
variance-covariance matrix

dimensional normal random variable with
where

. The element of V at position
is estimated as

T2 statistic can be constructed as

A Hotelling’s

which asymptotically follows a Chi-squared

distribution with

degrees of freedom. It is well known that the Hotelling’s T2 statistic has

low power when

is large, and that eliminating
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from the test statistic could lead to an

improvement in power (Bai and Saranadasa, 1996). Along this line, a squared score test (Pan
2009, referred to as “SSU”) and a kernel-machine based test with the linear kernel (Wu et al.
2010, referred to as “SKAT”) have increased power for testing multiple marker main effects.
These methods do not distinguish between the matching score effects and recipient SNP effects,
however, which may have different underlying biological mechanisms. The SKAT method, for
example, assumes that

and

have the same underlying variance component (Wu et al., 2011),

which therefore does not distinguish recipients’ SNP main effects and the effect of the matching
score.

Here we propose a new statistic as follows.

can be decomposed as

.

Our statistic is based on Eigen decomposition of matrix

Let

denote a

matrix with the pth column being the pth eigenvector of the sample variance-covariance
matrix

and

denote the corresponding eigenvalues. We extract

the first s (s < m) PCs (the choice of s is discussed below). Let
as the vector of

,

Define

Our test statistic is constructed based on

:

,

where

is the s x s identity matrix.

We can show that this statistic is asymptotically distributed as a Chi-squared random variable
with s+1 degrees of freedom under the null. Therefore,

is there under the null due to the

orthogonality between the eigenvectors. Under the alternative hypothesis, this statistic is
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distributed as a non-central Chi-squared random variable with s+1 degrees of freedom and noncentrality parameter that is equal to its value.

3.2.5 Selection of s for JST
Choosing the number of principal components to retain (s) is always a difficult task in principal
component analysis. One common method is to choose the number of PCs to keep based on a
predefined percentage of total variance explained. We utilize this method in our simulation
studies, looking at a range of 65-99% total variance explained by the retained PCs.

3.3 Simulations
Simulation studies were conducted to assess type I error and power levels of the JST, as well as
to determine the number of principal components to maintain after Eigen decomposition, s.

3.3.1 Simulation Study Design
Datasets were sampled from 1000 Genomes Phase 3 reference using HapGen2 (Su, Marchini
and Donnelly, 2011). Briefly, subsets of the reference data were created based on three gene
regions starting and ending positions, NAT2, CHI3L2, and ASAH1. These genes were chosen
due to their differing number of SNPs and LD structures (Figure B.1). SNPs with minor allele
frequency (MAF) less than 0.05 were excluded from analyses. The subset reference data was
then sampled with HapGen2 to generate 2n control individuals which were then paired into n
donor/recipient (D/R) pairs. A small sample size, n = 500, and a large sample size, n = 1000,
were considered. Recipient and donor genotype information was then extracted from these
datasets and used to calculate gene-based scores. A total of 5000 simulations were conducted
for each gene region and sample size combination.
For type I error analysis, null phenotypes were generated using the model

for binary outcome

, and using the model
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for continuous outcome
probability 0.5,

, where

is a binary covariate taking a value of either 0 or 1 with

is a continuous covariate drawn from a standard Normal distribution, and

is

an error term drawn from a standard Normal distribution.
For power analyses, phenotypes were generated using the model

for binary outcome

, or using the model

for continuous outcome

. For both models, a variety of true associations were tested, where

either recipient genotype SNPs were associated (
associated (

), or D/R matching was

. When recipient genotype SNPs were associated, we considered

scenarios in which 5, 15, or 25% of the SNPs in the gene region were truly associated with
outcome, and this group of SNPs was either in high linkage disequilibrium (LD) or low LD. When
D/R matching was associated, we considered scenarios in which 5, 15, 25, 50, 75, or 100% of the
SNPs in the gene region were important to match between D/R. For cases where less than 100%
of the SNPs were important to match, we included only the associated SNPs in the summed
matching score when deriving phenotypes, and then utilized the full gene-based matching score
for testing. Similarly to the recipient genotype SNPs, these groups of matched SNPs were either
in high or low LD with one another. We considered a small, 0.14, medium, 0.41, and a large,
0.69, effect size resulting in odds ratios of 1.25, 1.50, and 2.00. Prevalence of the binary outcome
ranged from 5-20% in order to see the effects of rare versus common outcomes. In addition,
several values of s were examined, accounting for 65 - 99% of total variance explained by the
principal components, to determine its effect on type I error and power levels. All analyses were
run using R (v4.0, R Core Team, 2021).
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3.3.2 Comparison to Existing Methods
In addition to testing the type I error and power levels of JST, we compared our method with a
standard GLM and the sequence kernel association test (SKAT). For all comparisons, phenotype
generation was the same as for JST. We used the same n x (m+1) matrix of combined recipient
genotype SNPs and gene-based D/R matching score as input as was used for JST. For our
standard GLM, we fit separate models under the null and alternative hypotheses respectively,
and then calculated the LRT statistic using the lrtest function from the lmtest (v0.9-37, Zeileis &
Hothorn, 2002) package in R. SKAT analysis was performed using the unweighted linear kernel
and the unweighted IBS kernel as implemented in the SKAT (v1.3.2.1, Lee, 2017) package in R.

3.3.3 Results of Simulation Studies
A subset of the total simulation results is presented for both type I error testing and power testing.
In all scenarios, results were similar for all combinations of gene, sample size, and any additional
variables tested. Table 3.1 is based on scenarios using NAT2 with 500 D/R pairs, and all figures
are based on 1000 D/R pairs, using data from either NAT2 or CHI3L2.

3.3.3.1 Type I Error

Table 3.1 shows the results of type I error rates for joint testing. For the proposed JST method,
the type I error rate was around 0.05 for all combinations of outcome prevalence and fitted genebased score. Type I error rates are nominal for s values between 65-90%, with some
conservative error rates seen with s = 99% for lower outcome prevalence. Similar results can be
seen for the SKAT method using either the linear or IBS kernel. The standard likelihood ratio test
based on generalized linear model tends to have inflated TIE values when the outcome is binary,
ranging from around 15% to 22%. When the outcome is continuous, the type I error is conserved.
Table 3. 1: Results of Type I Error simulations for the gene NAT2 with 500 D/R pairs. Method
refers to one of the four multi-marker methods used for testing. Score refers to the gene-based
score that was fit as part of the modeling. The columns Prevalence 20%, 10%, and 5% give
results for binary outcome Y, and the continuous column gives results for continuous outcome Y.
JST stands for Joint Score Test, with s value (percent of variance explained by the PCs) indicated
in parentheses. Results for s value between 70 and 95% were similar to those for s = 65%. SKAT
stands for Sequence Kernel Association Test. SKAT (Linear) refers to using SKAT with an
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unweighted linear kernel. SKAT (IBS) refers to fitting SKAT with an unweighted IBS kernel. GLM
stands for Generalized Linear Model.
Method

Score

JST (s = 65%)
JST (s = 65%)
JST (s = 65%)
JST (s = 65%)
JST (s = 99%)
JST (s = 99%)
JST (s = 99%)
JST (s = 99%)
SKAT (Linear)
SKAT (Linear)
SKAT (Linear)
SKAT (Linear)
SKAT (IBS)
SKAT (IBS)
SKAT (IBS)
SKAT (IBS)
GLM
GLM
GLM
GLM

IBS
Incompatibility
AMS
Binary MM
IBS
Incompatibility
AMS
Binary MM
IBS
Incompatibility
AMS
Binary MM
IBS
Incompatibility
AMS
Binary MM
IBS
Incompatibility
AMS
Binary MM

20%
0.05
0.05
0.05
0.05
0.04
0.05
0.04
0.04
0.05
0.05
0.05
0.05
0.05
0.06
0.05
0.05
0.22
0.24
0.22
0.22

Prevalence
10%
0.05
0.04
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.19
0.19
0.20
0.19

Continuous

5%
0.06
0.05
0.06
0.06
0.01
0.01
0.01
0.01
0.05
0.05
0.05
0.05
0.04
0.05
0.05
0.05
0.17
0.15
0.15
0.17

0.05
0.05
0.04
0.04
0.04
0.04
0.04
0.03
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.06
0.06
0.06
0.06

3.3.3.2 Power – Recipient Genotype SNPs Associated

Figure 3.1 shows results from power analyses where the recipient genotype SNPs are associated
with outcome, but the gene-based score is not associated. Under this scenario, SKAT using the
IBS kernel performs better than SKAT using the linear kernel, so we use the IBS kernel results for
our comparisons. The GLM LRT tends to have the lowest power, ranging from around 50%
(panels B and C) to around 80% (panel D). It is probable that the power levels in panel D are
being artificially inflated due to inflation of type I error rate. The power difference between the
proposed JST and SKAT using the unweighted IBS kernel varies. When the R genotype SNPs
associated with outcome are in low LD, JST tends to have higher power than SKAT, as seen in
the panel A of Figure 3.1 where JST with s = 95% reaches close to 90% power but SKAT does
not reach 80% power. When the SNPs associated with the outcome are in high LD, SKAT and
the JST method can have similar power levels. This can be seen in the panel B of Figure 3.1
where both SKAT and JST with s = 65-80% reach around 85% power. When the size of the gene
is increased, as in panels C and D, we see that JST tends to have higher power than SKAT in
both scenarios. Additionally, when a continuous outcome is examined, JST with any value of s
tends to have much higher power than SKAT using either kernel (Figure B.2).
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For this scenario, there is not a singular s value that always results in the highest power. Panels
A, and C of Figure 3.1 both show that JST has the highest power when s corresponds to 95%
variance explained. Panel B shows that under different circumstances, retaining a smaller
number of principal components may result in higher power, while the opposite is seen to be true
for panel D. We note that power levels for JST in all panels are around 80%, so changing the
number of principal components retained does not seem to drastically affect the overall power of
the method.

Figure 3. 1: Power estimates from simulations using the genes NAT2 (Panels A and B) and
CHI3L2 (Panels C and D) with 1000 pairs of donors and recipients under the scenario that
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recipient genotype SNPs were associated with outcome. Panels A and B show an outcome
prevalence of 10%. Panel C has an outcome prevalence of 5% and Panel D, 20%. Panels A-C
show results for a medium OR (1.25) and Panel D for a large OR (2.00). Panels A and C show
results when 25% of recipient SNPs are associated, while 15% are associated in Panel B and
only 5% in Panel D. In panels A and D, SNPs are in low LD while in panels B and C they are in
high LD. The four colored bars represent which gene-based score was fit in the model, with red
corresponding to the allogenomics mismatch score (AMS), orange to binary mismatch score,
green to identity-by-state (IBS) score, and blue to Incompatibility score. From left to right in
panels A, C, and D, the method used for model fitting was the joint score test (JST), with s values
of 85, 90, 95, and 99% of variance explained by the principal components (PCs), the sequence
kernel association test (SKAT) with the unweighted IBS kernel, and a generalized linear model
(GLM) likelihood ratio test (LRT). Panel B shows results for JST with s values of 65-80%. The yaxis shows estimated power from 0-100%. The horizontal blue line corresponds to 65% power
and the horizontal red line corresponds to 80% power.
3.3.3.3 Power – Donor/Recipient Gene-Based Matching Score Associated

Figure 3.2 shows an example of results on power when the D/R gene-based matching score was
associated with outcome and recipient genotype was not associated. Under this scenario, SKAT
performance is slightly better using the linear kernel versus the IBS kernel, so we use the linear
kernel results in our comparison. We can see that overall, SKAT has the highest power under
these simulation conditions, with power levels reaching at least 80% for all four associated
scores. The proposed JST method has the second highest power ranging from around 60% when
the binary mismatch score is associated to around 90% when the IBS score is associated. The
GLM LRT has the lowest power, ranging from around 25% to almost 65%. We note that JST
tends to have the highest power when the percentage of variance explained by the s PCs is the
smallest (65%). When the IBS gene-based score or the AMS is truly associated (panels A and C),
power tends to be higher overall than when the binary scores are associated, with all s values
leading to over 80% power. The Binary mismatch score being truly associated (panel B) tends to
have the lowest overall power of the four scores, with four scenarios in which power does not
reach 65%. Similar results are seen when outcome is continuous (Figure B.3).
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Figure 3. 2: Power estimates from simulations using the gene CHI3L2 and 1000 pairs of donors
and recipients under the scenario that the gene-based score was associated with outcome. All
plots shown are for a binary outcome with prevalence 10%. A small odds ratio (1.25) was used
for phenotype generation. For these simulations, 50% of SNPs in the gene score were associated
with the outcome, and these SNPs were in low LD. From left to right, and top to bottom the true
associated gene-score is the allogenomics mismatch score (AMS), the Binary Mismatch, the
identity-by-state (IBS), and the Incompatibility score. The four colors represent which score was
used to fit the model, where red is the AMS, yellow is the Binary Mismatch score, green is the
IBS, and blue is the Incompatibility score. In each plot, the x-axis corresponds to the method
used, where from left to right methods are joint score test (JST) with s values of 65, 70, 75, and
80% of variance explained by the principal components used, the sequence kernel association
test (SKAT) with unweighted linear kernel, and a generalized linear model (GLM) likelihood ratio
test (LRT). The y-axis shows estimated power from 0-100%. The horizontal blue line corresponds
to 65% power and the horizontal red line corresponds to 80% power.
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3.4 Real Data Analysis
3.4.1 Sample Information
Kidney transplant data was collected from two cohorts: Deterioration of Kidney Allograft Function
(DeKAF, 2005-2011, NCT00270712) Genomics Study and Genomics of Kidney Transplantation
(GEN-03, 2012-2016, NCT01714440) study. Genotypes from the DeKAF cohort (n = 784 donorrecipient pairs) were determined with the AFR‐AMR Axiom chip (Affymetrix, Santa Clara,
CA) (Hoffmann et al. 2011), which contains 837,930 variants. Genotyping of GEN-03 cohort (n =
404 donor-recipient pairs) was performed on a custom exome-plus Affymetrix TxArray SNP chip
(Li et al. 2015), which contains approximately 782,000 variants. Genotype calling was performed
in one batch on the Affymetrix Genotyping Console v4.0 using the GT1 algorithm, which is based
on BRLMM‐P (Affymetrix, Santa Clara, CA). Genotyping details can be found in the manuscript
by Oetting et al. (2016). Non-Caucasian recipients were excluded from this study.

3.4.2 Statistical Analysis
The common SNPs in the two cohorts were grouped by physical locations within 23,062 genomewide genes (GRCh38.p13) and then analyzed using both JST with s = 85% variance explained
and SKAT with an unweighted IBS kernel. Covariates were included for recipients’ age, gender,
PRA status, prior non-kidney transplantation, and an indicator for the cohort membership. Pvalues were adjusted for multiple comparisons using the Bonferroni procedure.

3.4.3 Results
Table 3.2 shows the top five genes from analysis of the combined GEN03 and DeKAF data sets
using JST with an s value of 85% and the top five genes from SKAT analysis of the combined
data sets, using an unweighted IBS kernel. Gene ranking is based on the smallest p-value for all
four score models. P-values for the four different models are relatively similar for each of the five
genes. The number of genotyped SNPs in the genes ranges from 3 to 15 for the JST results and
from 3 to 104 in the SKAT results. Only one of the top genes found using SKAT analyses was
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also found in the top five for JST analysis. None of the genes reach significance levels after

correcting for multiple comparisons, although the JST analyses tend to produce smaller p-values

than the SKAT analyses.

Table 3. 2: Results of JST and SKAT analysis of combined GEN03 and DeKAF data sets. The
top 5 genes sorted by p-value from fitting a model with the any of the four gene-based score are
shown. JST was calculated using p=85% of variance explained. SKAT was run using the IBS
kernel. Chr: chromosome, IBS: identity-by-state, Incomp: incompatibility, AMS: allogenomics
mismatch score, SNP: single nucleotide polymorphism.
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3.5 Discussion
We propose a multi-marker test statistic designed for use with paired genetic data in
transplantation. The joint score test, or JST, can be used for testing whether specific gene
regions are associated with transplant outcomes, either through the recipient genotype or D/R
genetic matching. Compared to other statistical tests in this setting, the JST has the potential for
increased power and reproducibility as compared to single SNP tests, as well as increased
interpretability as compared to multi-SNP methods that sum across large regions of the genome.
The Eigen decomposition of the recipient genotype covariance matrix allows for a potential
increase in power for JST as compared to a standard GLM likelihood ratio test. By transforming
the covariance matrix into its principal components, we are able to select only those components
that are most likely to be associated and discard the remaining components. We chose to keep
principal components with large eigenvalues in accordance with previous theoretical and
empirical work by Liu, Barnett, and Lin (2020) to have the greatest power to detect genetic
associations.
Our simulations showed that JST is a competitive method as compared to standard GLM, and
SKAT. Type I error rates were conserved for both JST and SKAT but were inflated for GLM. This
inflation could be due to the larger number of covariates being fit in this model. In power
simulations, JST tended to outperform SKAT when recipient genotype SNPs, in low LD with all
other SNPs in the region, were truly associated with outcome. When the recipient SNPs were in
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high LD, SKAT and JST performed similarly for the smallest gene but increasing the gene size
while keeping the percentage of associated SNPs constant led to JST surpassing SKAT in power.
These findings agree with those found by Liu, Barnett, and Lin (2020) where the SKAT method
performed closer to use of the first principal component when LD between SNPs increased, due
to the increase of the first eigenvalue weighting the first PC higher in the SKAT test statistic.
When gene-based score was associated with outcome, SKAT tended to have higher or similar
power to JST depending on which gene-based score was used in modeling. When the AMS and
IBS score were associated with the outcome, they tended to have higher power than when the
Binary Mismatch score and Incompatibility score were associated. Additionally, when the Binary
Mismatch score or Incompatibility score were associated with outcome, the AMS or IBS score
respectively maintained relatively high power. Following these observations, it is recommended
that the AMS or IBS score be used for testing. Ideally, the choice of score should be determined
based on prior knowledge of the genetic mechanism.
To the best of our knowledge, SKAT has not previously been evaluated under the scenario of
jointly testing for an association between a set of SNPs and a gene-based score and has not
been utilized with paired transplant genetics data. Our evaluation of SKAT under these
circumstances found that the method works well and is robust. We determined that the choice of
kernel often impacted power levels, however, such as when the SKAT method using the linear
kernel had minimal power as compared to the SKAT method using the IBS kernel under the
scenario where R genotype SNPs were associated with outcome. Investigation into this
phenomenon found that scaling the gene-based scores from between 0 and 1, before running
SKAT with a linear kernel leads to an improvement in power (Figure B.4). The IBS kernel had
relatively high power under both power scenarios, with power levels only about 5% less than
those of the linear kernel when gene-based score was associated, so use of the IBS kernel may
be preferred when the true underlying association is unknown.
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Based on the simulation studies, there is no clear value of s that leads to the highest power in all
scenarios. When gene-based score was associated with the outcome, the smallest s value we
considered tended to have the highest power, but power tended to be similar for s values
corresponding to between 65 and 80% variance explained by the PCs. When recipient genotype
SNPs were associated with the outcome, changing the value of s did not tend to drastically
change the power levels. Since the true association mechanism is unknown for real data
analysis, it may be beneficial to run models using a few different s values, although this will
increase the number of tests. An alternative is to choose a middling value of s, around 80 or 85%,
which tends to have high power under either scenario of association.
Our analysis of kidney transplant data found no statistically significant results after accounting for
multiple comparisons. This may be due to a variety of factors. First, we utilized a Bonferroni
correction threshold based on the total number of genes tested, 25,000, and the total number of
models fit for each gene, 4 to account for all the scores. We know that the scores are not actually
independent from each other, however, so this threshold is too strict. Second, even after
combining the two data sets, we were left with a relatively small sample size, and an especially
limited number of acute rejection (AR) cases. Based on our simulation studies, we know that it is
difficult to obtain high power for a lower outcome prevalence, which may be the case here.
Despite the lack of statistical significance, the top five genes determined with JST analysis
include genes that could plausibly lead to AR after kidney transplant. Three of the five genes,
IFNA5, Z98752.3, and SGK2, have been found to be associated with the immune system or
specific types of immune cells which could attack a transplanted kidney if the graft is recognized
as non-self (Chen et al., 2020, Kichaev et al., 2019). Given the small sample sizes prevalent in
transplant genetic studies, it may be wise to prioritize genes for analysis according to their
potential function to reduce the burden of multiple testing.
The JST method does have some limitations. Transplant data analysis was limited to data from
paired kidney transplant. The method can be applied to other organ data as well, as long as
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genotype data is available for both the donor and the recipient. For our simulation studies, we
only focused on unrelated D/R pairs, but it is possible that the degree of relatedness between a
donor and a recipient may impact whether the recipient experiences acute rejection. We were
able to look at related versus non-related pairs in our combined kidney data sets and found that
these two groups had no overlap in their top 5 potentially associated genes. Based on these
results, we believe it is important to account for relatedness between a D/R pair in analyses. We
restricted our analyses to only include common SNPs, but rare variants can be used in JST
analyses. If there is interest in the association of rare variants, it is possible to construct a
weighted version of the distance function as,

.
Then a simple weighting option that will help upweight rarer minor allele frequencies (MAFs) is

the use of

(Kwee et al., 2008).

In summary, the JST is a powerful method that can be used for the analysis of paired genetic
data. Use of this method could lead to the discovery of gene regions potentially important to
transplant outcome, which could be further studied to try and determine the biological
mechanisms behind acute rejection.
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CHAPTER 4

A COMPARISON OF HIGH-DIMENSIONAL ANALYSIS METHODS APPLIED TO
PAIRED TRANSPLANT DONOR/RECIPIENT GENETIC DATA
4.1 Introduction
Genetic matching in solid organ transplant has traditionally been restricted to the humanleukocyte antigen (HLA) region of the genome, but there is a growing body of evidence that
accounting for HLA mismatches alone is not enough to prevent negative long-term transplant
outcomes. While HLA mismatching remains an important risk factor for graft failure, there have
been instances of graft loss from antibody-mediated rejection in the case of HLA identical
donor/recipient (D/R) pairs, suggesting that non-HLA regions of the genome may also be
important for genetic matching in transplant (Pineda et al., 2017; Farouk et al., 2020; Mesnard et
al., 2016; Zanoni, & Kiryluk, 2020). D/R genetic matching at these so-called minor
histocompatibility antigens (mHAs) has been found to be associated with long-term graft survival
in kidney and liver transplant, and mismatched mHAs have been shown to evoke an immune
response in the recipient towards the donor organ, which may damage the organ and eventually
lead to allograft rejection (Zhang et al., 2020; Reindl‐Schwaighofer et al., 2020; Pineda et al.,
2017). To improve long-term outcomes of solid organ transplant, it is of interest to learn more
about which mHAs are potentially important for D/R genetic matching.
A few previous studies have examined D/R genetic matching and the possible association of
these matching effects with transplant outcomes. In their work, Mesnard et al. (2016) construct a
matching score based on the estimated number of amino acid mismatches that the donor
genome encodes for at a given protein position. They were able to find a negative linear
association between their allogenomics mismatch score (AMS) and estimated glomerular filtration
rate at 36 months post-transplant in three independent cohorts, suggesting that AMS may be
associated with long-term graft function (Mesnard et al., 2016). Another study focused on the
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genomic-collision hypothesis, in which a homozygous recipient, with two deletion tagging alleles,
is paired with a non-homozygous donor, that has at least one non-deletion tagging allele. They
were able to find a SNP in the LIMS1 gene region that was significantly associated with graft
rejection and were able to replicate these findings under the genomic-collision model using three
independent kidney transplant cohorts (Steers et al., 2019). Pineda et al. focused on the outcome
of antibody-mediated rejection after kidney transplant (2017). They determined that recipients
who had the outcome of antibody mediated rejection (AMR) had a significantly higher number of
mismatched mHA variants as compared to those recipients who did not have an AMR outcome
(Pineda et al., 2017). Additionally, a study by Reindl-Schwaighofer et al. (2019) found that the
degree of genome-wide genetic mismatch in non-synonymous SNPs was independently
associated with graft loss after adjusting for HLA eplet mismatch. These studies provide further
incentive for matching outside the minor histocompatibility complex (MHC) region of the genome,
but their various techniques are not without limitation.
The four previously mentioned studies all tended to look at D/R genetic mismatch across the
genome or a gene-region but did not account for any additional genetic effects that may be
present. Past genetic studies have found recipient genotype or donor genotype SNPs that are
separately associated with transplant outcomes (Yang & Sarwal, 2017; Almoguera, Shaked, &
Keating, 2014). Additionally, it has been shown that jointly testing the recipient genotype SNPs
and a SNP-based genetic matching score can lead to detection of either recipient genotype SNPs
associated with transplant outcome or SNPs for which D/R matching is associated with transplant
outcome (Arthur et al., 2020). Given that parts of the recipient genotype have been found to be
associated with transplant outcome separately from D/R matching, it is important to consider
these potential effects when conducting a test for association of D/R matching with transplant
outcome. This task can quickly grow complex, however, since the number of recipient SNPs in a
gene or gene region may increase rapidly. In the case of the matching scores used in the
previously discussed studies, recipient SNPs from across the genome would need to be
accounted for, leading to potential cases of high-dimensional data with the number of SNPs
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exceeding the number of available samples (p > n). In addition, associated recipient genotype
SNPs are not fully known, due to lack of replication in previous studies, but it is assumed that only
a small number of these SNPs are truly going to be associated with transplant outcome. To deal
with the potential high-dimensionality and the uncertainty of truly associated SNPs, it may be
necessary to utilize a high-dimensional method with a sparsity assumption for feature selection.
It is known that some classical inference methods may not perform well in the high-dimensional
setting, despite their asymptotic properties, due to the increase in dimensionality of the covariate
vector along with the increase in sample size (Wu, Xu, Shen, & Pan, 2020; Shi, Song, Chen, & Li,
2019; Janková, Shah, Bühlmann, & Samworth, 2020; Wu, Xu, & Pan, 2019; Voorman, Shojaie, &
Witten, 2014). This has led to the development of significance testing methods specifically made
for high-dimensional generalized linear models (GLMs), often focusing hypothesis testing on a
low-dimensional subset of the covariates that is determined using a penalty or other feature
selection method. Many of these methods utilize random sample splitting approaches, essentially
splitting the available sample in half, and using one half to perform feature selection and the
second half to fit a model using these selected features and to conduct inference (Wu, Xu, Shen,
& Pan, 2020; Janková, Shah, Bühlmann, & Samworth, 2020; Lee, Sun, Sun, & Taylor, 2016;
Zhang, & Zhang, 2014; van de Geer, Bühlmann, Ritov, & Dezeure 2014; Ning, & Liu, 2017).
Another common approach is conditional inference, where all inference is conducted under the
condition that a specific feature was selected to be in the final model (Ning, & Liu, 2017; Lee,
Sun, Sun, & Taylor, 2016; Shi, Song, Chen, & Li, 2019; Wu, Xu, Shen, & Pan, 2020). There are
also several methods that use bias-correction or projection to deal with the impact of highdimensional nuisance parameters, especially when the penalties used for feature selection are
known to produce biased estimates under these conditions (Shi, Song, Chen, & Li, 2019; Wu, Xu,
Shen, & Pan, 2020; Janková, Shah, Bühlmann, & Samworth, 2020; Voorman, Shojaie, & Witten,
2014; Javanmard, & Montanari, 2014; Ning, & Liu, 2017). While these methods have been used
on a variety of high-dimensional data sets, none have been specifically designed to be used with
paired genetic data. In order to determine which method may be best for our purposes, we have
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chosen four representative methods to compare in terms of type I error rate and power levels
when used for testing the association of gene-based matching score with transplant outcome
while accounting for potentially associated recipient genotype SNPs.
The rest of the chapter will be formatted as follows. In section 4.2 we will introduce the four
methods being compared, along with any common notation. Then we will discuss the simulation
methods used to estimate the type I error and power levels for these four methods under a variety
of different conditions in section 4.3. We will then discuss the results of the simulations in section
4.4 and compare the performance of the various methods in the final section.

4.2 Methods
We compare four hypothesis testing methods originally developed for use with high-dimensional
data in the context of testing for association of gene-based score with transplant outcome while
accounting for possible association of recipient genotype SNPs with outcome.

4.2.1 Notation
Suppose that we have n transplant donor/recipient (D/R) pairs, each with genotype data for p
SNPs. Define

as the numerical coding of the genotype of the jth marker for the ith recipient
, which can equal the number of minor alleles or another numerical

coding, and define

as the kth covariate of D/R pair i. Let Yi correspond to either a continuous

or categorical outcome for D/R pair i. We utilize a generalized linear model of the form

where g() is the link function,

, and

is the vector of K covariates for

D/R pair i with regression coefficients

Let

denote the

recipient genotype vector of p SNPs for recipient i with regression coefficients
where we allow for the possibility that p > n and also that

may be sparse. Also let

denote a

single gene-based genetic matching score value for D/R pair i with regression coefficient .
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can be calculated by summing a measure of distance between the donor and recipient genotypes
over the gene region of interest,

=

described in chapters 2 and 3. Note that

We utilize four distance measures which are
may include principal components (PCs) for

describing population substrata. We are interested in testing the null hypothesis
.

4.2.2 Partial Penalized Likelihood Ratio, Wald, and Score Tests
The first set of methods we are using for comparison are a partially penalized likelihood ratio
(LRT), Wald, and Score test proposed by Shi, Song, Chen and Li (2019). To simplify notation for
this method, define an n x q matrix

, where

, and a q-dimensional vector

is an n x 1 vector of 1 and

. Then express the probability density

function of Y in exponential form as

where

corresponds to error variance when the outcome is continuous and

when the

outcome is binary. These methods focus on testing null hypotheses of the form

, where

is a sub-vector of all the true regression coefficients from our GLM. We focus on the
hypothesis

, where

in our notation. Also define

to

be the number of restrictions set by the null hypothesis. For estimating coefficients under both the
null and alternative models, the partially penalized likelihood function

is utilized, where

is some penalty function with tuning parameter . Estimates of

null and alternative hypotheses are defined as
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under the

It is clear from the likelihood function that only parameters not involved in the null hypothesis are
penalized. For our purposes, penalties for

} were forced to be zero, so the covariates, W,

were guaranteed to be included in the final model, meaning only elements of

were penalized.

The partial penalized LRT is defined as

where

and

is a consistent estimator for

. The partial

penalized Wald test statistic is defined as

where

with

as a submatrix formed by the first m rows and columns of

, and

, corresponding to non-zero coefficients that are not included in the null
hypothesis, fit under the alternative model. The partial penalized score statistic is defined as

where

corresponds to non-zero coefficients that are not included in the

null hypothesis, fit under the null model, and
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The authors prove that for a fixed number of constraints, and a consistent estimator

for

, TL,

TW, and TS asymptotically converge to a Chi-square distribution with m degrees of freedom under
the null and a noncentral Chi-square under the alternative. To compute the estimators

and

, the authors utilize an algorithm based on alternating direction method of multipliers (ADMM)
and they use the SCAD penalty,

with a = 3.7, for dimension reduction (Shi, Song, Chen and Li, 2019). We utilize all three tests in
our comparison, since the sample size will be limited, and the methods may not necessarily
perform the same under these conditions.

4.2.3 Desparsified Lasso Estimator
The second method is a Wald test statistic based on the desparsified lasso estimator by van de
Geer, Bühlmann, Ritovi and Dezeure (2014). For a generalized linear model, this method is
based on desparsifying the

-norm regularized estimator

Karush-Kuhn-Tucker (KKT) conditions for
that is strictly convex in

using a method based on the

. Briefly, for a loss function

, they define

and

. Then our

-norm

regularized estimator is calculated as
..

and then construct the “relaxed form” of

To desparsify the estimator, they define a

the inverse of , defined as , using a nodewise lasso. Further details for calculating

can be

seen in van de Geer, Bühlmann, Ritovi and Dezeure (2014). Our estimator is then defined as

.
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The authors prove that

asymptotically follows a Gaussian distribution, which can be used to

construct a standard Wald test statistic using ,

,,
where

.

4.2.4 Decorrelated Score Statistic
The third method we utilize, the decorrelated score statistic, was proposed by Ning and Liu
(2017). This method aims to test hypotheses for low-dimensional parameters of interest in the
presence of high-dimensional nuisance parameters. Essentially, they partition the model
parameters

into a finite dimensional parameter of interest ( , a single parameter in the

majority of the manuscript, and the remaining nuisance parameters (
. They focus on testing the null hypothesis

,

, where

and
is the true value of

. To test this hypothesis in the presence of the nuisance parameters, they apply a decorrelation
operation on the high dimensional score function to obtain a decorrelated score function for
which is no longer correlated with the nuisance score functions.

Their method is flexible to both loss function and penalty function. In general,
using a penalized M-estimator approach as

is estimated

, for a loss function

and penalty function with tuning parameter ,

. The decorrelated score function is defined

as

where

and

. To construct a score test for the null hypothesis of interest

using the decorrelated score function, the nuisance parameters and the vector
using a three-step algorithm detailed in the original manuscript. First,
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are estimated

is calculated using the

penalized M-estimator equation and is partitioned into
Dantzig type estimator

,

and

. Then

is estimated by the

such that

is then estimated as

, and
. This estimated score is then used to

construct a score test statistic of the form

, where

the partial Fisher information matrix. The authors prove that

is an estimate of

follows an asymptotic normal

distribution (Ning and Liu, 2017).
To calculate the decorrelated score statistic, we used the same procedures as Shi, Song, Chen,
and Li (2019). Briefly, for a continuous outcome we estimated

with a penalized linear

regression with the SCAD penalty function and we estimated

using a penalized linear

regression with L1 penalty function. For binary outcome, we estimated
regression using the SCAD penalty and

with a penalized logistic

was again estimated using the penalized linear

regression with L1 penalty function. In either case, tuning parameters were determined using 10fold cross-validation.

4.2.5 Adaptive Interaction Sum of Powered Score (aiSPU) Test
The final method we will use for comparison is the adaptive interaction sum of powered score
(aiSPU) test proposed by Wu, Xu, Shen, and Pan (2020). This method is also constructed under
the generalized linear model framework and focuses on testing for association with p variables of
interest ( ) while dealing with q nuisance parameters (

when p and q are both large. To

estimate the coefficients for the nuisance parameters under the null hypothesis, the authors apply
a penalized regression method. In the manuscript, they focus on using the non-convex truncated
lasso penalty but for our comparisons we will be utilizing the SCAD penalty because there were
instances where the model using a truncated lasso penalty would not converge properly when
running simulations. Unlike the desparsified lasso and the decorrelated score tests, the aiSPU
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test can be given a subset of covariates to remain unpenalized, so we can guarantee that the
covariates

have non-penalized coefficients in all models.

An adaptive test is constructed by considering the score vector for p-dimensional ,
, where

,(

null hypothesis using the penalized regression model and
for

and

are estimated under the
. We also denote

. The authors propose the interaction sum of

powered score (iSPU) class of tests with power index

as

.
They also define

,
where

is the

covariance matrix with element

manuscript shows that the power of

for

is dependent on the unknown

. The original
under specific

alternatives. The adaptive interaction sum of powered score (aiSPU) test is a way to combine
multiple iSPU tests with differing values of

to try and maintain high power across a variety of

alternatives. The aiSPU statistic is defined as
,
where

is the p-value for

.

P-values for iSPU and aiSPU can be computed using their asymptotic distributions or using a
parametric bootstrap. The authors recommend using a parametric bootstrap for small p, since the
asymptotic theory may not hold under these conditions. Since we are using p=1 to test only for
the gene-based matching score effect, we use the parametric bootstrap to calculate p-values for
both iSPU and aiSPU for our comparisons.
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4.3 Simulations
Simulations were conducted to compare the type I error rates and power levels of the four highdimensional methods.

4.3.1 Data Generation
Paired D/R genetic data was created by sampling from 1000 Genomes Phase 3 reference using
HapGen2 software. Briefly, datasets from the reference were subset based on the gene regions
NAT2, CHI3L2, and ASAH1 based on the gene region starting and ending points. Quality control
was performed to remove uncommon SNPs (MAF < 0.05) from the analyses. HapGen2 was then
used to sample the subset data and 2n control individuals were generated. These were then
paired into n donor/recipient pairs where n = 500 or n = 1000.

4.3.2 Phenotype Generation
For type I error analyses, null phenotypes were generated under the model

for a binary outcome , and under the model

for a continuous outcome. For all models,
p=0.5 and

values were drawn from a Binomial distribution with

values were drawn from a standard Normal distribution. The error term, , was also

drawn from a standard Normal distribution.
In addition, phenotypes were also generated under the model

for binary outcome , and under the model

60

for continuous outcome , corresponding to when matching score is not associated with
outcome, but recipient genotype is associated. Under these scenarios, we tested type I error
rates for

values corresponding to odds ratios of 1.25, 1.50, and 2.00. We also looked at

situations where either 5, 15, or 25% of the SNPs in

were truly associated with outcome and

these SNP sets were either in low or high LD.
For power analyses, phenotypes were also generated for two distinct scenarios. We first focused
on the scenario when matching score is associated with outcome, but recipient genotype SNPs
are not associated. For this setting, we generated phenotypes using the model

for binary outcome , and using the model

for continuous outcome . Under this scenario, we looked at

values corresponding to odds

ratios of 1.25, 1.50, and 2.00, and we examined the power levels when either 5, 15 or 25% of
SNPs were important for matching, where these SNPs were either in low or high LD with the
other SNPs in the gene region. We were also interested in testing the power levels when both
matching score and recipient genotype SNPs are associated with outcome. For this setting, we
generated phenotypes under the model

for a binary outcome and under the model

for continuous outcome. We looked at

and

values corresponding to odds ratios of 1.25, 1.50,

and 2.00 where effect sizes were not necessarily equal. We also used a range of 5,15, or 25% of
recipient genotype SNPs being associated with outcome and 5, 15, or 25% of SNPs were
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important for matching. In each case, SNPs were either in low or high LD with the other SNPs in
the gene region. After phenotypes were generated, each of the four high-dimensional methods
was fit and hypothesis testing was conducted for our null hypothesis of interest. A standard GLM
likelihood ratio test was also fit as a comparison to the high-dimensional methods. A total of 3000
simulations were conducted for each possible model for both type I error and power simulations.
Type I error analyses were conducted first, and power analyses were subsequently conducted
only using the high-dimensional methods that did not show inflated type I error rates under either
of the phenotype generation scenarios.

4.4 Simulation Results
4.4.1 Type I Error Estimation
Table 4.1 shows estimated type I errors rates under the scenario that neither recipient genotype
SNPs nor gene matching score are associated with outcome. Results are presented for the gene
ASAH1 with 500 donor/recipient pairs, but results are similar for a larger sample size and for the
smaller genes. For a binary outcome, we see that type I error is estimated to be nominal for the
partial penalized Wald and Score tests, as well as for the aiSPU. The partial penalized LRT and
the decorrelated score test have slightly inflated type I error estimates, ranging from around 1217%. The GLM shows highly inflated type I error estimates, ranging from 40-50%. This inflation is
not present when looking at the two smaller genes, however. In addition, the desparsified lasso
has very conservative estimates of type I error, often dipping below 1%. For a continuous
outcome, the partial penalized LRT, and Wald test, as well as the desparsified lasso and the
aiSPU maintain nominal type I error rates. The partial penalized score test, as well as the GLM
and the decorrelated score have slightly inflated type I error rates, ranging from around 7-13%.
Table 4. 1: Estimated type I error rates for the gene ASAH1 with 500 donor/recipient pairs under
the scenario that neither recipient genotype SNPs nor gene matching is associated with outcome
(
). TL = Partial penalized likelihood ratio test, TW = Partial penalized Wald test, TS =
Partial penalized score test, Decorr. Score = decorrelated score test, Incomp = incompatibility
score.
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Outcome
Prevalence

20%

10%

5%

Cont.

Score
Used

TL

TW

TS

GLM

Desparse
Lasso

Decorr.
Score

aiSPU

IBS

0.11

0.05

0.05

0.40

0.0123

0.13

0.06

Incomp.

0.12

0.05

0.05

0.39

0.0137

0.13

0.05

AMS

0.11

0.04

0.05

0.38

0.0107

0.13

0.05

Binary
Mismatch

0.12

0.06

0.06

0.40

0.013

0.12

0.06

IBS

0.13

0.06

0.05

0.47

0.0057

0.14

0.05

Incomp.

0.12

0.06

0.04

0.46

0.006

0.14

0.06

AMS

0.11

0.04

0.05

0.46

0.0037

0.14

0.05

Binary
Mismatch

0.13

0.05

0.06

0.46

0.0043

0.14

0.05

IBS

0.12

0.06

0.05

0.52

0.0107

0.16

0.05

Incomp.

0.12

0.06

0.05

0.54

0.0083

0.16

0.05

AMS

0.12

0.05

0.05

0.53

0.004

0.17

0.05

Binary
Mismatch

0.12

0.04

0.05

0.53

0.008

0.17

0.05

IBS

0.05

0.05

0.08

0.06

0.045

0.11

0.05

Incomp.

0.05

0.04

0.08

0.07

0.0453

0.12

0.06

AMS

0.05

0.05

0.08

0.07

0.0483

0.12

0.06

Binary
Mismatch

0.05

0.04

0.07

0.07

0.0417

0.13

0.04

Table 4.2 shows estimated type I error rates under the scenario that recipient genotype SNPs are
associated with outcome, but gene matching is not associated. Results are presented for the
gene ASAH1 with 1000 D/R pairs. When outcome is binary, the type I error rates for the aiSPU
method tend to be nominal for all combinations of OR size, percent R SNPs associated, and low
or high LD between associated SNPs. The decorrelated score test also gives nominal estimates
for the largest binary prevalence, but tends to give more conservative estimates, between 2 and
4%, for the smaller prevalence values. The desparsified lasso once again shows very
conservative type I error estimates, with some values estimated as less than 0.01. We see that

63

under this scenario, the GLM continues to have inflated type I error values, ranging from around
20 to 80%. GLM estimates are not as highly inflated for the smaller genes, however. The partial
penalized tests show varying estimates, with the likelihood ratio test, TL, tending to have the
highest inflation values overall, from 10 to 56%, with higher inflation for a larger number of
associated R SNPs and higher LD between these associated SNPs. An exception to this occurs
when 5% of R SNPs are associated, and the inflation level tends to decrease when dealing with
high LD as compared to low LD SNPs. The Wald and Score tests, TW and TS, have similar
estimates, but the partial penalized Wald test tends to have slightly higher inflation than the partial
penalized score test. All tests with inflated type I error estimates tend to follow the trends of
increased inflation when either effect size, LD or percent of associated SNPs increases, except
for the previously stated exception. For continuous outcomes, the desparsified lasso and
decorrelated score give nominal estimates. The aiSPU test gives mostly nominal estimates but
has some slightly inflated values, between 7 and 16%, for situations where effect size is large or
medium with R SNPs in high LD, or effect size is small and 25% of R SNPs, which are in high LD,
are associated with outcome. The GLM values are also inflated, ranging from 23 to over 70%. For
a continuous outcome, the partial penalized Wald test tends to fair slightly better than the Score
and LRT, but all values are still inflated for this group of tests.

4.4.2 Statistical Power Analysis Results
For a binary outcome, only the desparsified lasso test and the aiSPU test maintained non-inflated
type I error estimates under both phenotype generation scenarios, so we focus on these two tests
for our power analysis. While the desparsified lasso test was the only method that did not show
inflated type I error rates under a continuous outcome, we choose to compare it to aiSPU using
only the scenarios where aiSPU did not show an inflated type I error estimate.
Table 4. 2: Estimated type I error rates for the gene ASAH1 with 1000 donor/recipient pairs
under the scenario that recipient genotype SNPs are associated with outcome, but gene
matching is not associated (γ=0, β≠0). TL = Partial penalized likelihood ratio test, TW = Partial
penalized Wald test, TS = Partial penalized score test, Decorr. Score = decorrelated score test.
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Outcome
Prevalence

OR
Size

Percent R
SNPs
Assoc.

5% R
SNPs

Small
OR

15% R
SNPs

25% R
SNPs

5% R
SNPs

20%

Medium
OR

15% R
SNPs

25% R
SNPs

5% R
SNPs

Large
OR

15% R
SNPs

25% R
SNPs

5% R
SNPs

Small
OR

15% R
SNPs

25% R
SNPs

10%

5% R
SNPs
Medium
OR
15% R
SNPs

LD

TL

TW

TS

GLM

Desparse
Lasso

Decorr.
Score

aiSPU

Low LD

0.14

0.06

0.05

0.51

0.0077

0.04

0.06

High LD

0.13

0.07

0.07

0.53

0.0093

0.04

0.06

Low LD

0.13

0.08

0.07

0.54

0.0093

0.04

0.06

High LD

0.25

0.19

0.18

0.63

0.0067

0.03

0.05

Low LD

0.23

0.16

0.14

0.58

0.007

0.05

0.05

High LD

0.38

0.31

0.24

0.69

0.007

0.04

0.05

Low LD

0.29

0.07

0.05

0.54

0.0073

0.05

0.04

High LD

0.23

0.17

0.15

0.58

0.0067

0.04

0.05

Low LD

0.33

0.15

0.12

0.60

0.0043

0.05

0.05

High LD

0.49

0.44

0.29

0.80

0.01

0.04

0.05

Low LD

0.50

0.26

0.20

0.69

0.0073

0.04

0.05

High LD

0.53

0.49

0.28

0.71

0.008

0.04

0.05

Low LD

0.34

0.09

0.07

0.54

0.0073

0.04

0.05

High LD

0.35

0.29

0.23

0.67

0.0073

0.04

0.05

Low LD

0.40

0.10

0.07

0.68

0.0043

0.04

0.05

High LD

0.56

0.49

0.29

0.67

0.009

0.05

0.06

Low LD

0.50

0.14

0.12

0.62

0.0037

0.05

0.05

High LD

0.53

0.49

0.29

0.45

0.0123

0.05

0.05

Low LD

0.14

0.06

0.04

0.57

0.002

0.03

0.05

High LD

0.12

0.07

0.07

0.60

7e-04

0.03

0.06

Low LD

0.11

0.06

0.06

0.60

0.0017

0.03

0.06

High LD

0.15

0.11

0.10

0.68

0.0023

0.03

0.06

Low LD

0.16

0.11

0.10

0.64

7e-04

0.04

0.06

High LD

0.23

0.17

0.15

0.74

3e-04

0.04

0.06

Low LD

0.20

0.07

0.05

0.58

0

0.04

0.05

High LD

0.16

0.10

0.09

0.67

3e-04

0.03

0.06

Low LD

0.18

0.11

0.10

0.69

0

0.04

0.06

High LD

0.30

0.26

0.22

0.74

7e-04

0.03

0.05
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Outcome
Prevalence

OR
Size

Percent R
SNPs
Assoc.

25% R
SNPs

5% R
SNPs

Large
OR

15% R
SNPs

25% R
SNPs

5% R
SNPs

Small
OR

15% R
SNPs

25% R
SNPs

5% R
SNPs

5%

Medium
OR

15% R
SNPs

25% R
SNPs

5% R
SNPs

Large
OR

15% R
SNPs

25% R
SNPs

Cont.

Small
OR

5% R
SNPs

LD

TL

TW

TS

GLM

Desparse
Lasso

Decorr.
Score

aiSPU

Low LD

0.25

0.20

0.17

0.65

0

0.04

0.05

High LD

0.33

0.30

0.25

0.51

3e-04

0.04

0.05

Low LD

0.28

0.08

0.06

0.61

7e-04

0.04

0.05

High LD

0.22

0.17

0.15

0.73

7e-04

0.03

0.05

Low LD

0.24

0.17

0.13

0.70

0

0.04

0.06

High LD

0.34

0.29

0.23

0.46

0

0.04

0.05

Low LD

0.31

0.21

0.16

0.54

0

0.04

0.05

High LD

0.35

0.30

0.25

0.30

7e-04

0.04

0.05

Low LD

0.11

0.06

0.05

0.61

0.006

0.02

0.05

High LD

0.10

0.06

0.05

0.66

0.006

0.02

0.06

Low LD

0.12

0.07

0.06

0.64

0.0043

0.03

0.05

High LD

0.12

0.07

0.07

0.71

0.004

0.02

0.06

Low LD

0.12

0.07

0.07

0.68

0.004

0.03

0.06

High LD

0.16

0.11

0.10

0.72

0.003

0.03

0.06

Low LD

0.15

0.06

0.05

0.64

0.0013

0.03

0.05

High LD

0.12

0.07

0.07

0.71

0.0037

0.02

0.06

Low LD

0.13

0.08

0.07

0.66

3e-04

0.03

0.05

High LD

0.19

0.13

0.13

0.57

3e-04

0.03

0.06

Low LD

0.16

0.11

0.11

0.55

3e-04

0.02

0.05

High LD

0.21

0.15

0.14

0.34

0

0.03

0.05

Low LD

0.18

0.06

0.05

0.64

0.0017

0.03

0.04

High LD

0.14

0.10

0.09

0.72

3e-04

0.03

0.06

Low LD

0.15

0.10

0.10

0.62

0

0.03

0.06

High LD

0.19

0.15

0.14

0.31

0.001

0.03

0.04

Low LD

0.18

0.13

0.12

0.45

0

0.03

0.05

High LD

0.21

0.16

0.14

0.23

0

0.03

0.04

Low LD

0.17

0.06

0.81

0.68

0.047

0.05

0.05

High LD

0.34

0.35

0.37

0.72

0.041

0.06

0.06
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Outcome
Prevalence

OR
Size

Percent R
SNPs
Assoc.

15% R
SNPs

25% R
SNPs

5% R
SNPs

Medium
OR

15% R
SNPs

25% R
SNPs

5% R
SNPs

Large
OR

15% R
SNPs

25% R
SNPs

LD

TL

TW

TS

GLM

Desparse
Lasso

Decorr.
Score

aiSPU

Low LD

0.42

0.46

0.95

0.68

0.0487

0.06

0.05

High LD

0.31

0.16

0.17

0.72

0.0437

0.05

0.06

Low LD

0.43

0.38

0.57

0.68

0.0493

0.06

0.05

High LD

0.47

0.18

0.25

0.72

0.0443

0.05

0.10

Low LD

0.06

0.06

0.09

0.55

0.0477

0.06

0.05

High LD

0.29

0.17

0.17

0.34

0.043

0.05

0.06

Low LD

0.30

0.30

0.37

0.55

0.0453

0.05

0.06

High LD

0.67

0.21

0.61

0.34

0.0413

0.06

0.16

Low LD

0.31

0.20

0.37

0.55

0.039

0.06

0.05

High LD

0.81

0.31

0.90

0.34

0.0443

0.05

0.16

Low LD

0.05

0.05

0.05

0.45

0.052

0.06

0.05

High LD

0.42

0.17

0.26

0.23

0.047

0.06

0.08

Low LD

0.80

0.43

0.82

0.45

0.0463

0.06

0.05

High LD

0.82

0.27

0.91

0.23

0.0427

0.06

0.10

Low LD

0.71

0.33

0.80

0.45

0.0443

0.05

0.04

High LD

0.84

0.45

0.90

0.23

0.0443

0.05

0.07

Figure 4.1 shows the results of power analyses under the scenario where only gene-based
matching is associated with outcome. These results are representative of all combinations of
gene, sample size, etc. used for phenotype generation. We see that no matter which gene-based
score is truly associated with outcome, the aiSPU test has higher power than the desparsified
lasso test. In addition, we see that the models fit with related scores, the IBS and incompatibility
scores and the AMS and binary mismatch scores, have very similar power to each other in all
scenarios. Results of power analyses for a continuous outcome when only gene-based matching
score is associated with outcome can be seen in Figure 4.2. Under this scenario, aiSPU still
tends to have higher power than the desparsified lasso method but the difference between the
power levels is much smaller as compared to the binary outcome.
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Figure 4. 1: Estimated power levels for the aiSPU test and the desparsified lasso test for the gene
NAT2 with 500 donor/recipient pairs when only gene-based matching score is associated with
outcome (γ≠0, β=0). Phenotypes were generated using an outcome prevalence of 20%, with a
medium odds ratio (1.50) and 25% of SNPs were important for matching (4 SNPs), and the
associated SNPs were in low LD with the remaining SNPs in the gene region. Panels a-d show
results when the AMS, binary mismatch, IBS, and incompatibility gene-based matching scores
are truly associated with outcome, respectively. The colored bars show which gene-based score
was used for fitting each model. Red corresponds to the AMS, orange to the binary mismatch
score, green to the IBS, and blue to the incompatibility score. The horizontal blue line marks 65%
power and the horizontal red line marks 80% power.
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Figure 4. 2: Estimated power levels for the aiSPU test and the desparsified lasso test for the gene
NAT2 with 500 donor/recipient pairs when only gene-based matching score is associated with
outcome (γ≠0, β=0). Phenotypes were generated using a continuous outcome, with a small odds
ratio (1.25) and 25% of SNPs were important for matching (4 SNPs), and the associated SNPs
were in low LD with the remaining SNPs in the gene region. Panels a-d show results when the
AMS, binary mismatch, IBS, and incompatibility gene-based matching scores are truly associated
with outcome, respectively. The colored bars show which gene-based score was used for fitting
each model. Red corresponds to the AMS, orange to the binary mismatch score, green to the
IBS, and blue to the incompatibility score. The horizontal blue line marks 65% power and the
horizontal red line marks 80% power.
Figure 4.3 shows the results of power analyses under the scenario that both gene-based
matching score and a percentage of the recipient SNPs are associated with outcome. Two
different scenarios are presented in Figure 4.3, one where the gene-based matching score is
associated with a medium OR, (1.50) and the recipient SNPs are associated with a small OR
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(1.25) and the opposite configuration where gene-based matching score has a small OR and
recipient SNPs have a medium OR association. We see that aiSPU still tends to have higher
power than the desparsified lasso when the gene-based matching score has the smaller effect
size. When the gene-based matching score has a medium OR, however, the power differential
between the aiSPU and the desparsified lasso methods is negligible. The OR associated with the
gene-based matching score tends to affect the power of aiSPU less than it affects the power of
the desparsified lasso, since for three of the four scores the aiSPU has almost identical power for
a small and medium effect size for the gene-based matching score.

Figure 4. 3: Estimated power levels for the aiSPU test and the desparsified lasso test for the gene
NAT2 with 500 donor/recipient pairs when both gene-based matching score and recipient SNPs
are associated with outcome (γ≠0, β≠0). Phenotypes were generated using an outcome
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prevalence of 10%, with 5% of SNPs being important for matching (4 SNPs), 5% of recipient
SNPs being associated, and all associated SNPs were in low LD with the remaining SNPs in the
gene region. Panels a-d show results when the AMS, binary mismatch, IBS, and incompatibility
gene-based matching scores are truly associated with outcome, respectively. The colored bars
show which gene-based score was used for fitting each model. Red corresponds to the AMS,
orange to the binary mismatch score, green to the IBS, and blue to the incompatibility score. The
horizontal blue line marks 65% power and the horizontal red line marks 80% power.

4.5 Discussion
We compared four high-dimensional analysis methods for association testing of a gene-based
D/R matching score while accounting for potentially high dimensional recipient SNP associations.
All four methods had different ways of dealing with the inherent difficulties of high-dimensional
data analysis. The partial penalized tests only apply penalties to parameters not constrained by
the null hypothesis and the authors derive asymptotic distributions of each test. The desparsified
lasso test removes bias in the estimated parameter values, which then allows the authors to
derive the asymptotic distribution of the new estimator. The decorrelated score test attempts to
remove correlation between the parameters being tested and any nuisance parameters in the
model. The aiSPU test combines multiple interaction sum of powered score tests to maintain a
high level of power for association testing. It was of interest to determine if any of these methods
were superior when it comes to testing for association with a paired D/R gene-based matching
score.
Type I error simulations showed that the partial penalized tests tended to have inflated type I
error values under the simulation settings used. There are a few potential explanations for this
inflation. First, our simulation settings differed from those discussed in the original manuscript.
Their tests were originally constructed for use with ultrahigh dimension data, where the number of
covariates increased exponentially with sample size, but this was not how our simulated data was
constructed. The most likely explanation, given the most drastic type I error inflations occurred
when recipient SNPs in high LD with the remaining SNPs in the region were associated with
outcome, is that the method does not perform as well when the data is highly correlated. In the
original manuscript, the authors looked at independent and autoregressive covariance structures
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but the covariance between SNPs in a gene can often be complex and does not follow either of
these basic structures. If the high amount of SNP correlation is truly causing the inflated type I
error rates, it is possible that these methods would perform better using data that has been LD
pruned.
The decorrelated score test also showed inflated type I error rates when neither gene-based
matching score nor recipient SNPs were associated with outcome but showed improvements in
type I error estimates when recipient SNPs were associated with outcome. Investigation into the
score values showed that scores tended to be skewed to larger values when neither value was
associated with outcome and this skewness tended to resolve itself when recipient SNPs were
associated. It is possible that the subtracted term, concerning the score of the nuisance
parameters, is estimated to be smaller when no association exists, leading to an overall larger
value of the decorrelated score statistic. It is also possible that the covariates used in phenotype
creation are being treated as nuisance parameters by the test, since there is no option to force
the fitting of any variable values not in the null hypothesis. If the covariates are included in the
subtracted term, it is possible that they are artificially lowering the covariance values for the
recipient SNPS and thus causing the entire subtracted term to be lower. If this is the case, then a
slight modification to the method may result in more nominal type I error rates.
The power of the aiSPU test was higher than that of the desparsified lasso method under many
different simulation scenarios. This was not surprising, as the type I error values of the
desparsified lasso method tended to be much more conservative than all other methods, less
than 0.01 in some instances, which could translate to a larger number of false negative results in
subsequent power analyses. These conservative results may come as a consequence of
debiasing the lasso estimates, since we observed that the desparsified estimates, , tended to be
fractional nonzero values in instances where a covariate was not associated with outcome. These
estimates were about half positive and half negative in sign, which may lead to a smaller sum
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overall when a final test statistic is calculated. These smaller statistics would lead to fewer
significant p-values and would explain the conservative nature of the test.
Our simulation study is not without limitations. We focused on comparing four high-dimensional
methods for their ability to test for a gene-based matching score association with outcome, while
correcting for potential recipient SNP effects. It is possible that another high-dimensional method
we did not examine would work well under these circumstances. This work could be furthered by
exploring more methods in the future. We also focused our simulations on situations when the
recipient SNPs we were accounting for were located on the same gene that the matching score
was representative of. More exploration should be done under the scenario that recipient SNPs
are located on a separate gene or across several genes as compared to the matching score of
interest, as this may better reflect true biological mechanisms of transplant genetics.
In this study we compared four high-dimensional analysis methods to determine if any was
superior in testing for an association between a gene-based matching score and transplant
outcome, while also accounting for separate associations of recipient SNPs. We determined that
the aiSPU method was best to use, as it offered a combination of nominal type I error rates and
high power under a variety of simulation scenarios. The desparsified lasso method also showed
favorable results but had more conservative type I error rates and lower power levels at times.
The partial penalized tests seemed to have difficulty dealing with the amount of correlation
present between SNPs in some gene regions, and may work better using LD pruned data,
although some information would be lost. The decorrelated score test showed inflated type I error
estimates under some scenarios. Overall, these methods all fared better than a generalized linear
model since they could account for issues inherent in high-dimensional analysis. Highdimensional methods can work well with paired genetic data, and perhaps utilizing these methods
in future studies can give more insight into genetically important regions in transplant.
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CHAPTER 5
DISCUSSION
In this dissertation we studied various methods for association testing of genetic data from
transplant donor/recipient pairs. We found that many of these methods can be useful for
identifying genetic regions implicated in transplant outcomes. We also propose methods that are
specifically designed for use with paired genetic data, which allows us to test for matching effect
associations. These methods are generalizable and can be used in non-transplant settings with
other paired genetic data, such as the mother-child setting.
In Chapter 2 we focused on single SNP matching between transplant donors and recipients,
proposing a new matching score to measure D/R genetic distance and comparing it to three
existing scores that had not been rigorously tested previously. Our work showed that different
distance measures can be used to specify differing biological mechanisms behind the transplant
outcome of interest. Scores like the AMS, for example, which focus on donor alleles the recipient
might see as non-self suggest a mechanism in which donor-specific antibodies are produced by
the recipient immune system to attack the donor organ. A more general score, like the IBS
mismatch score, leaves open the possibility of the opposite mechanism, which would present as
graft-vs-host disease. This allows us to choose a distance measure based on prior knowledge, so
if a donor organ is not able to produce immune cells after transplantation, for example, it might
make sense to choose a score that prioritizes recipient immune response.
We also found that jointly testing for recipient SNP effects and D/R genetic matching effect was a
powerful way to determine SNPs associated with transplant outcome. Based on preliminary
research for this work, we determined that previous studies showing recipient genotype or donor
genotype associations were important to incorporate into our analyses, as it was possible that
these effects were separate from any genetic matching effects present. Our liver data analyses
seemed to agree with this hypothesis, since there were instances where the recipient SNP was
associated with acute rejection and none of the matching scores were associated.
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Utilizing the joint testing approach also gave us a starting point for our extension to a multi-marker
method, which we discussed in Chapter 3. Our proposed Joint Score Test proved to be a
powerful technique for testing for gene-regions associated with transplant outcome, performing
well compared to other commonly used methods. JST is also extremely flexible, allowing for
different gene-based matching scores to be used and permitting the recipient genotype data and
the matching score data to encompass separate regions of the genome. This is an important
consideration, since it is plausible that regions of the genome that are important for
donor/recipient matching are not the same as regions in the recipient genome that are associated
with transplant outcome. The flexibility of the gene-based matching scores is also vital, as it
allows us to focus on different biological mechanisms and can also be altered to target more
common or rarer variants. A weighted matching score could be utilized to upweight the impact of
rare variant matching, for example, which would result in greater power for detecting associations
with rare variants.
In Chapter 4 we focused on testing for matching score association separately, while accounting
for potential recipient genotype associations. We utilized existing high-dimensional analysis
techniques and applied them to paired genetic data. Our simulation study showed that using
these techniques for testing for D/R genetic matching score associations was plausible and gave
insight into difficulties that arise when testing these data sets. Some of the techniques did not
seem to account for the high correlation between SNPs in the gene region, for example. It is
possible that some of these methods may fare better under a more extreme scenario, perhaps
testing for gene-based association and including the entire recipient genome as potential
covariates, since their original derivation assumes an extremely large number of features. Future
tests should try to replicate this scenario and should perhaps expand the high-dimensional
methods being tested in order to acquire knowledge as to which techniques used in highdimensional tests tend to result in better performance with paired genetic data.
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There are many ways in which the approaches discussed in this dissertation could be expanded
upon for future study. It is of interest to test these methods using various types of solid organ
transplant data. While we have shown that these methods are useful in the case of liver and
kidney transplant data, they can also be used to gain more insight into regions important for
genetic matching in heart or lung transplant. There are also opportunities to utilize these methods
with different transplant outcomes. Our work focused on the outcome of acute rejection after
transplant, but it is known that this outcome is difficult to define without an invasive biopsy to
confirm it. This may have made it more difficult to detect true associations in our data analyses.
Other transplant outcomes, such as those related to immunosuppression metabolism or the onset
of diabetes after transplant, are more well defined and should be explored in future analyses.
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APPENDIX A
SUPPLEMENTARY MATERIALS FOR CHAPTER 2
A.1 Derivation of OR relationship
Under this example, the true odds ratio would be of the form

,
while the fitted odds ratio is of the form

.
Using Bayes Theorem, we can express the fitted odds ratio in term of the true odds ratio,

This odds ratio can be further simplified into

𝑂𝑅𝐹𝑖𝑡
𝑂𝑅𝑇𝑟𝑢𝑒 +

=
𝑂𝑅𝑇𝑟𝑢𝑒 ∙

𝑃(𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝑌 = 1|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝑌 = 0|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0)
+
+
𝑃(𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝑌 = 1|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝑌 = 0|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1)

𝑃 𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0 𝑃 𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1
𝑃 𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1 𝑃 𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0

𝑂𝑅𝑇𝑟𝑢𝑒 +

𝑂𝑅𝐹𝑖𝑡 =
𝑂𝑅𝑇𝑟𝑢𝑒 ∙

+1+

𝑃(𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝑌 = 1|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝑌 = 0|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0)
+
𝑃(𝐺𝑟𝑝 = 0, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝑌 = 1|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝐺𝑟𝑝 = 1, 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝑌 = 0|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1)

2
(1 − 𝑀𝐴𝐹2 )
(1 − 𝑀𝐴𝐹2 ) 𝑃(𝑌 = 1|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1) 𝑃(𝑌 = 0|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0)
+
+
4
𝑃(𝑌 = 1|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0) 𝑃(𝑌 = 0|𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1)
𝑀𝐴𝐹
𝑀𝐴𝐹2

1 − 𝑀𝐴𝐹2
𝑀𝐴𝐹4

Assuming that the outcome

2

+1+

1 − 𝑀𝐴𝐹2
𝑀𝐴𝐹2

𝑃 𝑌 = 1 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1
𝑃 𝑌 = 1 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0

is rare, such that

+

𝑃 𝑌 = 0 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 0
𝑃 𝑌 = 0 𝑆𝐼𝑛𝑐𝑜𝑚𝑝 = 1

, the sum
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.

Substituting this into the formula gives the equation presented in the main text.

A.2 Supplementary Tables and Figures
Table A. 1: The average odds ratios (ORs) by minor allele frequency (MAF) for each of the
models used in marginal power analysis. Column one shows the score or genotype that was used
to create the phenotype values, the true model, and columns three-seven represent the five
models that were fit, including the true model and four misspecified models. Incomp.:
Incompatibility Score, AMS: Allogenomics Mismatch Score
True
Model
Covariate

SNP
MAF

Average Odds Ratio
IBS
Recipient
Mismatch
Genotype
Score

Recipient
Genotype

IBS Mismatch
Score

Incompatibility
Score

Incomp.
Score

Binary
Mismatch
Score

AMS

0.05

1.46

0.86

0.85

1.05

1.00

0.10

1.46

0.90

0.89

1.07

1.01

0.20

1.48

0.84

0.83

1.00

0.99

0.30

1.45

0.96

0.97

1.07

1.02

0.40

1.46

0.93

0.93

1.08

1.02

0.50

1.51

0.83

0.83

0.98

0.97

0.05

0.83

1.45

1.50

1.38

1.34

0.10

0.88

1.45

1.53

1.38

1.32

0.20

0.76

1.44

1.46

1.39

1.36

0.30

0.95

1.45

1.57

1.40

1.31

0.40

0.92

1.45

1.56

1.39

1.31

0.50

0.76

1.43

1.44

1.38

1.36

0.05

0.86

1.35

1.45

1.30

1.22

0.10

0.92

1.31

1.46

1.27

1.17

0.20

0.78

1.39

1.43

1.35

1.30

0.30

0.97

1.26

1.45

1.23

1.14

0.40

0.95

1.28

1.46

1.24

1.15
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Binary
Mismatch Score

Allogenomics
Mismatch Score

0.50

0.76

1.41

1.44

1.37

1.34

0.05

1.04

1.21

1.23

1.44

1.31

0.10

1.04

1.21

1.25

1.45

1.30

0.20

1.05

1.20

1.21

1.43

1.38

0.30

1.03

1.21

1.27

1.45

1.26

0.40

1.03

1.21

1.26

1.44

1.26

0.50

1.06

1.20

1.21

1.41

1.35

0.05

1.00

1.30

1.28

1.56

1.44

0.10

0.99

1.35

1.32

1.60

1.45

0.20

1.02

1.24

1.23

1.49

1.42

0.30

1.00

1.40

1.37

1.64

1.44

0.40

0.99

1.38

1.35

1.59

1.45

0.50

1.04

1.22

1.22

1.42

1.41

Table A. 2: Hazard ratios and 95% confidence intervals for all scores that reached a joint p-value
threshold of 0.05 or lower. Results are based on joint testing model where only Caucasian
recipients were used. †Results reach significance after Bonferroni correction.

Gene Region

RSID

IBS Mismatch

Incompatibility

Score
Hazard
Ratio
Joint
(95%
P-Value
CI)

Score
Hazard
Ratio
Joint
(95%
P-Value
CI)

Allogenomics
Mismatch
Score
Hazard
Ratio
Joint
(95%
P-Value
CI)

rs4335

rs4343
ACE
rs4353

rs4363

rs2640539

AGTR1

rs2639364

rs931490

1.00
(0.81,
1.23)
1.40
(1.10,
1.80)
1.33
(1.01,
1.75)
1.41
(1.08,
1.85)

0.03

0.94
(0.72,
1.23)

0.01

0.03

0.89
(0.72,
1.10)
1.36
(1.09,
1.71)

0.02

7.63E-03

0.03
1.30
(1.01,
1.66)

0.01
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0.03

Binary Mismatch
Score
Hazard
Ratio
Joint P(95%
Value
CI)
0.76
(0.56,
0.01
1.02)
0.76
(0.56,
0.01
1.02)
0.81
(0.67,
0.04
1.09)
0.75
†4.74E(0.55,
03
1.00)

rs3772622

CCR5

rs2856758

rs1029153

rs10900027

0.84
(0.63,
1.12)
0.83
(0.66,
1.05)
1.00
(0.79,
1.27)

0.04

0.01

0.02

0.82
(0.60,
1.12)
0.80
(0.61,
1.07)
1.03
(0.76,
1.39)

0.04

0.01

0.02

rs11592974

rs1159931

rs1436926

0.85
(0.61,
1.18)
1.47
(1.12,
1.92)

0.03
2.56
E-03

0.85
(0.59,
1.21)
1.45
(1.08,
1.95)

0.03

0.01

rs17883887
CXCL12
rs197453

1.19
(0.95,
1.50)

0.03

1.31
(1.09,
1.57)
0.77
(0.57,
1.04)
0.94
(0.75,
1.18)
1.05
(0.85,
1.31)
1.35
(1.07,
1.69)
0.76
(0.53,
1.10)
1.45
(1.13,
1.87)
1.38
(1.12,
1.70)
1.23
(1.01,
1.51)

0.02

0.02

0.04

0.02

1.31
(1.04,
1.66)
1.40
(1.10,
1.79)

rs4948877

0.01

2.39E-03

0.01

0.01

0.04

1.10E-02

rs4366439

rs17156139

rs800323

rs3024613
IL4R
rs4787423

1.26
(1.00,
1.59)
1.38
(1.12,
1.70)
1.90
(1.21,
2.97)

0.02

0.01

1.49
(1.11,
2.01)

0.02

0.03

1.24
(1.00,
1.54)
1.29
(1.07,
1.56)
1.44
(1.11,
1.86)

0.97
(0.71,
1.31)
1.14
(0.84,
1.54)

0.01

0.04

0.01

0.05

rs10508884

rs12573553

0.71
(0.50,
1.02)

0.02

0.72
(0.47,
1.09)
1.53
(1.13,
2.08)
1.50
(1.11,
2.02)
1.20
(0.90,
1.62)
1.38
(1.02,
1.86)
1.41
(1.04,
1.91)
1.58
(1.16,
2.15)
1.41
(1.05,
1.89)
1.44
(1.06,
1.95)
1.23
(0.92,
1.66)

0.01

3.27E-03

0.03

0.04

0.03

0.04

0.01

0.04

0.05

0.05

0.04

0.03

0.76
rs11070834

(0.58,
1.01)
0.80
(0.60,
1.06)

TNFAIP8L3
rs12443062

TNFRSF10A

rs11777928

1.37

0.04

0.03
1.35
(1.11,
1.63)

0.02
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0.01

1.49
(1.13,
1.96)

0.02
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0.01

1.44
(1.06, 1.94)
0.02

1.85E-03

1.62
(1.20, 2.19)

1.44
(1.08, 1.92)

0.02

0.01

0.02

0.01

1.31
(1.04, 1.65)

1.39
(1.09, 1.76)

rs4948877

1.35
(1.08, 1.68)

1.46
(1.07, 1.97)

rs17156139

rs3024613

rs12443062

0.03

0.01

0.01

1.29
(1.07, 1.56)

0.74
(0.57, 0.97)

1.49
(1.11, 2.01)

0.02

4.65E-03

1.49
(1.13, 1.96)

1.90E-03

1.35
(1.12, 1.63)

† 4.49E-03
2.57E-03

rs11777928

1.34
(1.10, 1.65)

0.73
(0.56, 0.95)

rs11070834

TNFRSF10A

1.38
(1.12, 1.71)

0.04

rs4366439

4.78E-03

rs12573553

TNFAIP8L3

1.29
(1.01, 1.65)

rs11592974

IL4R

0.74
(0.60, 0.91)

rs10900027

CXCL12

Table A. 3: Hazard ratios and 95% confidence intervals for all scores that reached a marginal pvalue threshold of 0.05 or lower. Results are based on Caucasian recipients only. Only SNPs that
reached joint significance were tested for marginal significance. †Results reach significance after
Bonferroni correction.
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2.76E-03

0.03

3.86E-03

1.43
(1.12, 1.83)

1.59
(1.17, 2.15)

0.01

4.19E-03

0.03

0.74
(0.56, 0.98)

0.72
(0.54, 0.97)

1.33
(1.07, 1.66)

1.31
(1.09, 1.57)

0.05

1.24
(1.00, 1.53)

0.01

1.34
(1.06, 1.69)

rs1029153

0.02

0.78
(0.62, 0.97)

4.80E-03

0.75
(0.62, 0.92)

rs197453

0.04

0.01

0.65
(0.47, 0.89)

rs1159931

0.03

0.04

1.28
(1.01, 1.62)

rs800323

1.25
(1.01, 1.56)

0.04

1.31
(1.01, 1.71)

rs1436926

0.76
(0.59, 0.98)

0.03

rs2856758

0.03

rs2640539

1.38
(1.02, 1.85)

rs3772622

CCR5

1.24
(1.03, 1.51)

rs4343

AGTR1

0.01

1.48
(1.10, 1.99)

2.47E-03

1.38
(1.12, 1.70)

rs17883887

0.02

1.41
(1.05, 1.89)

rs10508884

0.72
(0.54, 0.97)

0.03

0.72
(0.54, 0.97)

0.03

Hazard
Ratio
(95% CI)

P-Value

Binary
Mismatch
Score

P-Value

Hazard
Ratio
(95% CI)

Allogenomics
Mismatch
Score

P-Value

Hazard
Ratio
(95% CI)

Incompatibility
Score

P-Value

IBS
Mismatch
Score

Hazard
Ratio
(95% CI)

0.03
0.03
0.01
P-Value

0.81
(0.67, 0.98)
1.24
(1.03, 1.50)
1.29
(1.07, 1.56)
Hazard
Ratio
(95% CI)

P-Value

Hazard
Ratio
(95% CI)

Donor
Genotype

Recipient
Genotype

rs4353
rs4335
RSID

rs4363

ACE
Gene Region

Table A. 4: Example of haplotypes sampled for simulations. Gene TNFAIP8L3 (48 SNPs)
haplotypes and population frequencies.
Haplotypes
221421124334221443423141111424343233111322424432
421421124324221341423143332224143433333122222232
423443114123421413241343312243123233313322222232
441241124324221443423143311224343233113142442211
421421323323221443221133312223123233313324422232
423443114124221341423143332224143433333122222232
423443114124221443423141311424343233113322424432
221421124323421413241343312243123233313322222232
423443114123421413241343312243123233313322424432
423441324324221443423141311424343233113324422232
423443114124221443423143312224343233313122424232
441241124324221443423143311224343233113142222232
221421124334221443423141111424343233111322222232
421421124323243443221143312223121211313122422232
441241124323243443221143312223121211313142222232
421421124324221443423141111424343233111322424432
423443114123421413241343312243123233313324422232
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Frequency
(0.230)
(0.066)
(0.055)
(0.052)
(0.040)
(0.029)
(0.026)
(0.019)
(0.015)
(0.014)
(0.014)
(0.014)
(0.012)
(0.012)
(0.012)
(0.011)
(0.011)

Table A. 5: All gene regions used to create sample haplotypes. Starting and ending positions
correspond to HG37.
Gene

Number of
SNPs

Chromosome Starting Location Ending Location
(HG37)
(HG37)

ACE

15

17

61554422

61575741

AGTR1

16

3

148415658

148460790

CCL5

4

17

34198495

34207797

CCR2

4

3

46395225

46402419

CD28

59

2

204571198

204603635

CTLA4

6

2

204732509

204738683

CXCL12

68

10

44793038

44881941

HMOX1

2

22

35777060

35790207

IFNL3

2

19

39734246

39735646

IL4R

38

16

27325161

27376099

MASP2

14

1

11086580

11107296

MBL2

15

10

54525140

54532578

SELE

10

1

169691781

169703220

TGFB1

7

19

41836812

41859831

TLR4

15

9

120466460

120479768

TNFAIP8L3

48

15

51348798

51397473

TNFRSF6B

4

20

62328004

62330051

TNFRSF8

59

1

12123434

12204264

TNFRSF10A

14

8

23048970

23082680

TNFRSF13B

27

17

16842398

16875432

TNFSF9

8

19

6531010

6535939

TNFSF15

12

9

117546915

117568408
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Figure A. 1: Estimated type I error values by minor allele frequency for the five models when 1000
donor/recipient pairs were generated. The left side shows uncorrected type I error values, while
the right side shows Bonferroni corrected type I error values. The top panels show results for an
outcome incidence of 15% and the bottom panels show results for an outcome incidence of 30%.
The horizontal line on the left-side plots corresponds to the nominal significance level of 0.05. The
horizontal line on the right-side plots corresponds to the Bonferroni significance level of 0.001
(0.05/48 SNPs).

Type I Error Analysis
Figure A.1 shows the type I error results, both uncorrected and Bonferroni corrected. Overall, in
the uncorrected analyses there does not appear to be a clear trend between MAF and estimated
type I error for any of the five models. In general, for both outcome incidence levels, most of the
type I error values are below the nominal 0.05, and those that are higher do not tend above 0.06
which implies these models have a suitable false-positive rate. The Bonferroni corrected type I
error values have a larger spread, but again there is no pattern of over or under estimation for
any of the five methods. Results were similar for the smaller sample size of 500 donor/recipient
pairs.
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APPENDIX B
SUPPLEMENTARY MATERIAL FOR CHAPTER 3
B.1 Derivation of the JST Statistic (Binary Y i)
Let

denote the vector of covariates for adjustment, which may include PCs

for capturing population substructure. Our JST test statistic was based on the following logistic
regression model,

We would like to test the null hypotheses
denote estimates of
by regressing

and
and

. Let

and

under the null, which are obtained

only on the covariates

but not X or Z. Let

denote the predicted probability of

Define

and

under

.

as

and

.

Then the marginal likelihood score function for

under the null can be shown

equal to

,

and the marginal likelihood score function for

under the null can be shown equal to

,
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By standard Taylor series expansion, these can be further written as

and

.

Note that

and

are solutions to the following score equation:

Standard Taylor series expansion leads to the following,

.
After rearranging the terms, we obtain

.

Therefore,

can be written as

or equivalently,
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Similarly,

can be written as

or equivalently,

Further, let

denote the fitted value for the jth recipient genotype SNP for the ith recipient from

the weighted linear regression model

and let

denote the fitted

value for the gene-based genetic matching score of D/R pair i from a weighted linear regression
model

. In both cases, the weights are

for

recipient i or D/R pair i. Following standard weighted ordinary least squares procedures, we

calculate that

and

This leads to

and

So, for testing the
jth SNP, it is easy to see that the jth component of

and testing

, is equivalent to
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,

is equivalent to

.

If we let

and

we can write U in matrix form as

. The matrix V can therefore be computed using the formula provided in
the text.

B.2 Derivation of the JST Statistic (Continuous Y i)
Let

denote the vector of covariates for adjustment, which may include PCs

for capturing population substructure. Our JST test statistic was based on the following linear
regression model,

We would like to test the null hypotheses
denote estimates of
by regressing

and
and

. Let

and

under the null, which are obtained

only on the covariates

Then the marginal likelihood score function for

but not X or Z.

under the null can be shown

equal to

,
and the marginal likelihood score function for

under the null can be shown equal to

,
By standard Taylor series expansion, these can be further written as

and
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.

Note that

and

are solutions to the following score equation:

Standard Taylor series expansion leads to the following,

.
After rearranging the terms, we obtain

.

Therefore,

can be written as

,
or equivalently,

Similarly,

can be written as

,
or equivalently,
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Further, let

denote the fitted value for the jth recipient genotype SNP for the ith recipient from

the linear regression model

and let

denote the fitted value for

the gene-based genetic matching score of D/R pair i from a linear regression model
. Following ordinary least squares procedures, we can see that

and

For testing the jth SNP, it is easy to see that the jth component of

,

is equivalent

to

and testing

, is equivalent to

.
If we let

and

we can write U in matrix form as
. The matrix V can therefore be computed using the formula

provided in the text.
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B.3 Supplementary Tables and Figures
Table B. 1: Corresponding number of SNPs that are associated with outcome for genes NAT2,
CHI3L2, and ASAH1 based on the percent of SNPs associated with outcome.
Percent of SNPs
Associated with
Outcome
5
15
25
50
75
100

Number of SNPs
Associated with
Outcome – NAT2
1
2
4
7
11
14

Number of SNPs
Associated with Outcome
– CHI3L2
2
5
8
17
25
33

Number of SNPs
Associated with
Outcome – ASAH1
2
6
10
20
30
40

Figure B. 1: Haploview plots showing number of SNPs and LD structure for genes NAT2 (Block
A), CHI3L2 (Block B), and ASAH1 (Block C) used in simulation analyses.

92

Figure B. 2: Power estimates from simulations using 1000 pairs of donors and recipients under
the scenario that recipient genotype SNPs were associated with continuous outcome. Panel A
shows the scenario when data from NAT2 was sampled, a medium odds ratio (1.50) was used for
phenotype generation and 5% of recipient genotype SNPs were associated with the outcome and
were in low LD. Panel B shows the scenario when data from ASAH1 was sampled, a small odds
ratio (1.25) was used for phenotype generation and 15% of recipient genotype SNPs were
associated with the outcome and were in low LD. The four colored bars represent which genebased score was fit in the model, with red corresponding to the allogenomics mismatch score
(AMS), orange to binary mismatch score, green to identity-by-state (IBS) score, and blue to
Incompatibility score. From left to right in each plot, the method used for model fitting was the
joint score test (JST), with s values of 85, 90, 95, and 99% of variance explained by the principal
components (PCs), the sequence kernel association test (SKAT) with the unweighted linear and
unweighted IBS kernel, and a generalized linear model (GLM) likelihood ratio test (LRT). The yaxis shows estimated power from 0-100%. The horizontal blue line corresponds to 65% power
and the horizontal red line corresponds to 80% power.
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Figure B. 3: Power estimates for simulations using the gene NAT2 and 1000 donor/recipient
pairs under the scenario that the gene-based score was associated with continuous outcome. A
small odds ratio (1.25) was used for phenotype generation. For these simulations, 25% of SNPs
in the gene score were associated with the outcome, and these SNPs were in low LD. From left
to right, and top to bottom the true associated gene-score is the allogenomics mismatch score
(AMS), the Binary Mismatch, the identity-by-state (IBS), and the Incompatibility score. The four
colors represent which score was used to fit the model, where red is the AMS, yellow is the
Binary Mismatch score, green is the IBS, and blue is the Incompatibility score. In each plot, the
x-axis corresponds to the method used, where from left to right methods are joint score test
(JST) with s values of 65, 70, 75, and 80% of variance explained by the principal components
used, the sequence kernel association test (SKAT) with unweighted linear kernel, and a
generalized linear model (GLM) likelihood ratio test (LRT). The y-axis shows estimated power
from 0-100%. The horizontal blue line corresponds to 65% power and the horizontal red line
corresponds to 80% power.
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Figure B. 4: Power estimates from simulations using data from NAT2 and 1000 pairs of donors
and recipients under the scenario that recipient genotype SNPs were associated with outcome. In
both panels, outcome prevalence was 10%, a medium OR (1.50) was used, and 25% of recipient
SNPs were associated with outcome and were in low LD. Panel A shows the scenario when
SKAT is fit using a linear kernel and the gene-based scores are unscaled. Panel B shows the
scenario when SKAT is fit using a linear kernel and gene-based scores are scaled to a range of
0-1. The four colored bars represent which gene-based score was fit in the model, with red
corresponding to the allogenomics mismatch score (AMS), orange to binary mismatch score,
green to identity-by-state (IBS) score, and blue to Incompatibility score. From left to right in each
plot, the method used for model fitting was the joint score test (JST), with s values of 85, 90, 95,
and 99% of variance explained by the principal components (PCs), the sequence kernel
association test (SKAT) with the unweighted linear and unweighted IBS kernel, and a generalized
linear model (GLM) likelihood ratio test (LRT). The y-axis shows estimated power from 0-100%.
The horizontal blue line corresponds to 65% power and the horizontal red line corresponds to
80% power.

95

BIBLIOGRAPHY
Ajuebor, M. N., Carey, J. A., & Swain, M. G. (2006). CCR5 in T cell-mediated liver
diseases: what’s going on?. The Journal of Immunology, 177(4), 2039-2045.
https://doi.org/10.4049/jimmunol.177.4.2039
Almoguera, B., Shaked, A., & Keating, B. J. (2014). Transplantation genetics: current
status and prospects. American Journal of Transplantation, 14(4), 764-778.
https://doi.org/10.1111/ajt.12653
Arthur, V. L., Guan, W., Loza, B., Keating, B., & Chen, J. (2020, August 11). Joint testing
of donor and recipient genetic matching scores and recipient genotype has
robust power for finding genes associated with transplant outcomes. Genetic
Epidemiology; 44. https://doi.org/10.1002/gepi.22349
Bacanu, S.A. (2012). On Optimal Gene-Based Analysis of Genome Scans: Gene-Based
Analysis of Genome Scans. Genetic Epidemiology, 36(4), 333–339.
https://doi.org/10.1002/gepi.21625
Bai, Z., & Saranadasa, H. (1996). Effect of high dimension: by an example of a two
sample problem. Statistica Sinica, 6(2), 311-329.
Ballard, D.H., Cho, J., & Zhao, H. (2010). Comparisons of multi-marker association
methods to detect association between a candidate region and disease. Genetic
Epidemiology, 34(3), 201-12. https://doi.org/10.1002/gepi.20448
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004). Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics, 21(2), 263-265.
https://doi.org/10.1093/bioinformatics/bth457
96

Chen, L.S., Hsu, L., Gamazon, E.R., Cox, N.J., & Nicolae, D.L. (2012). An exponential
combination procedure for set-based association tests in sequencing studies.
American Journal of Human Genetics, 91(6), 977-86.
https://doi.org/10.1016/j.ajhg.2012.09.017
Chen, H., Huffman, J. E., Brody, J. A., Wang, C., Lee, S., Li, Z., Gogarten, S. M., Sofer,
T., Bielak, L. F., Bis, J. C., Blangero, J., Bowler, R. P., Cade, B. E., Cho, M. H.,
Correa, A., Curran, J. E., de Vries, P. S., Glahn, D. C., Guo, X., … Lin, X. (2019).
Efficient Variant Set Mixed Model Association Tests for Continuous and Binary
Traits in Large-Scale Whole-Genome Sequencing Studies. The American
Journal of Human Genetics, 104(2), 260–274.
https://doi.org/10.1016/j.ajhg.2018.12.012
Chen, M.H., Raffield, L. M., Mousas, A., Sakaue, S., Huffman, J. E., Moscati, A., Trivedi,
B., Jiang, T., Akbari, P., Vuckovic, D., Bao, E. L., Zhong, X., Manansala, R.,
Laplante, V., Chen, M., Lo, K. S., Qian, H., Lareau, C. A., Beaudoin, M., …
Lettre, G. (2020). Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in
746,667 Individuals from 5 Global Populations. Cell, 182(5), 1198-1213.e14.
https://doi.org/10.1016/j.cell.2020.06.045
Chen, S.X., & Qin, Y.L. (2010). A Two-Sample Test for High-Dimensional Data with
Applications to Gene-Set Testing. Annals of Statistics, 38(2), 808-35.
https://doi.org/10.1214/09-AOS716
Choudhary, N. S., Saigal, S., Bansal, R. K., Saraf, N., Gautam, D., & Soin, A. S. (2017).
Acute and chronic rejection after liver transplantation: what a clinician needs to

97

know. Journal of Clinical and Experimental Hepatology, 7(4), 358-366.
https://doi.org/10.1016/j.jceh.2017.10.003
Chiu, C., Yuan, F., Zhang, B., Yuan, A., Li, X., Fang, H., Lange, K., Weeks, D. E.,
Wilson, A. F., Bailey-Wilson, J. E., Musolf, A. M., Stambolian, D., Lakhal-Chaieb,
M. L., Cook, R. J., McMahon, F. J., Amos, C. I., Xiong, M., & Fan, R. (2019).
Linear mixed models for association analysis of quantitative traits with nextgeneration sequencing data. Genetic Epidemiology, 43(2), 189–206.
https://doi.org/10.1002/gepi.22177
Dai, J. Y., Kooperberg, C., Leblanc, M., & Prentice, R. L. (2012). Two-stage testing
procedures with independent filtering for genome-wide gene-environment
interaction. Biometrika, 99(4), 929-944. https://doi.org/10.1093/biomet/ass044
de Leeuw, C. A., Mooij, J. M., Heskes, T., & Posthuma, D. (2015). MAGMA: Generalized
Gene-Set Analysis of GWAS Data. PLOS Computational Biology, 11(4),
e1004219. https://doi.org/10.1371/journal.pcbi.1004219
Dogan, N., Hüsing-Kabar, A., Schmidt, H. H., Cicinnati, V. R., Beckebaum, S., & Kabar,
I. (2018). Acute allograft rejection in liver transplant recipients: Incidence, risk
factors, treatment success, and impact on graft failure. Journal of International
Medical Research, 46(9), 3979-3990. https://doi.org/10.1177/0300060518785543
Dorr, C. R., Oetting, W. S., Jacobson, P. A., & Israni, A. K. (2018). Genetics of Acute
Rejection After Kidney Transplantation. Transplant International, 31(3), 263-277.
https://doi.org/10.1111/tri.13084

98

Fan, R., & Knapp M. (2003). Genome association studies of complex diseases by casecontrol designs. American Journal of Human Genetics, 72(4), 850-68.
https://doi.org/10.1086/373966
Fan, R., Wang, Y., Mills, J. L., Wilson, A. F., Bailey-Wilson, J. E., & Xiong, M. (2013).
Functional Linear Models for Association Analysis of Quantitative Traits. Genetic
Epidemiology, 37(7), 726–742. https://doi.org/10.1002/gepi.21757
Farouk, S., Zhang, Z., & Menon, M. C. (2020). Non-HLA donor-recipient mismatches in
kidney transplantation - A stone left unturned. American Journal of
Transplantation, 20(1), 19-24. https://doi.org/10.1111/ajt.15612
Gauderman, W.J., Murcray, C., Gilliland, F., & Conti, D.V. (2007). Testing association
between disease and multiple SNPs in a candidate gene. Genetic Epidemiology,
31(5), 383-95. https://doi.org/10.1002/gepi.20219
Grafft, C. A., Cornell, L. D., Gloor, J. M., Cosio, F. G., Gandhi, M. J., Dean, P. G.,
Stegall, M. D., & Amer, H. (2009). Antibody-mediated rejection following
transplantation from an HLA-identical sibling. Nephrology Dialysis
Transplantation, 25(1), 307-310. https://doi.org/10.1093/ndt/gfp526
Green, D. J., Brooks, M. M., Burckart, G. J., Chinnock, R. E., Canter, C., Addonizio, L.
J., Bernstein, D., Kirklin, J. K., Naftel, D. C., Girnita, D. M., Zeevi, A., & Webber,
S. A. (2017). The Influence of Race and Common Genetic Variations on
Outcomes After Pediatric Heart Transplantation. American Journal of
Transplantation, 17(6), 1525-1539. https://doi.org/10.1111/ajt.14153

99

Hernandez-Fuentes, M. P., Franklin, C., Rebollo-Mesa, I., Mollon, J., Delaney, F.,
Perucha, E., Stapleton, C., Borrows, R., Byrne, C., Cavalleri, G., Clarke, B.,
Clatworthy, M., Feehally, J., Fuggle, S., Gagliano, S. A., Griffin, S., Hammad, A.,
Higgins, R., Jardine, A., … the United Kingdom and Ireland Renal Transplant
Consortium (UKIRTC) and the Wellcome Trust Case Control Consortium
(WTCCC)-3. (2018). Long- and short-term outcomes in renal allografts with
deceased donors: A large recipient and donor genome-wide association study.
American Journal of Transplantation, 18(6), 1370–1379.
https://doi.org/10.1111/ajt.14594
Hoffmann, T. J., Kvale, M. N., Hesselson, S. E., Zhan, Y., Aquino, C., Cao, Y., Cawley,
S., Chung, E., Connell, S., Eshragh, J., Ewing, M., Gollub, J., Henderson, M.,
Hubbell, E., Iribarren, C., Kaufman, J., Lao, R. Z., Lu, Y., Ludwig, D., Mathauda,
G. K., … Risch, N. (2011). Next generation genome-wide association tool: design
and coverage of a high-throughput European-optimized SNP array. Genomics,
98(2), 79–89. https://doi.org/10.1016/j.ygeno.2011.04.005
Hütter, G. (2011). The Impact of CCR5 Polymorphism on the Clinical Outcome of
Allogeneic Stem Cell Transplantation. Journal of Transplantation Technologies &
Research, 1, 2161-0991. https://doi.org/10.4172/2161-0991.S1-004
Iribarren, C., Lu, M., Jorgenson, E., Martínez, M., Lluis-Ganella, C., Subirana, I., Salas,
E., & Elosua, R. (2018). Weighted Multi-marker Genetic Risk Scores for Incident
Coronary Heart Disease among Individuals of African, Latino and East-Asian
Ancestry. Scientific Reports, 8(1), 6853. https://doi.org/10.1038/s41598-01825128-x
100

Janková, J., Shah, R. D., Bühlmann, P., & Samworth, R. J. (2020). Goodness-of-fit
testing in high dimensional generalized linear models. Journal of the Royal
Statistical Society: Series B (Statistical Methodology), 82(3), 773–795.
https://doi.org/10.1111/rssb.12371
Javanmard, A., & Montanari, A. (2014). Conﬁdence Intervals and Hypothesis Testing for
High-Dimensional Regression. Journal of Machine Learning Research, 15, 28692909.
Julian, B. A., Gaston, R. S., Brown, W. M., Reeves‐Daniel, A. M., Israni, A. K., Schladt,
D. P., Pastan, S. O., Mohan, S., Freedman, B. I., & Divers, J. (2017). Effect of
Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor
Risk Index. American Journal of Transplantation, 17(6), 1540-1548.
https://doi.org/10.1111/ajt.14113
Keating, B. J., Van Setten, J., Jacobson, P. A., Holmes, M. V., Verma, S. S.,
Chandrupatla, H. R., Nair, N., Gao, H., Li, Y. R., Chang, B., Wong, C., Phillips,
R., Cole, B. S., Mukhtar, E., Zhang, W., Cao, H., Mohebnasab, M., Hou, C., Lee,
T., Steel, L., ... & Wong, C. (2015). Design and Implementation of the
International Genetics and Translational Research in Transplantation Network.
Transplantation, 99(11), 2401-2412.
https://doi.org/10.1097/TP.0000000000000913
Kichaev, G., Bhatia, G., Loh, P.-R., Gazal, S., Burch, K., Freund, M. K., Schoech, A.,
Pasaniuc, B., & Price, A. L. (2019). Leveraging Polygenic Functional Enrichment
to Improve GWAS Power. The American Journal of Human Genetics, 104(1),
65–75. https://doi.org/10.1016/j.ajhg.2018.11.008
101

Kraft, P., Yen, Y. C., Stram, D. O., Morrison, J., & Gauderman, W. J. (2007). Exploiting
Gene-Environment Interaction to Detect Genetic Associations. Human Heredity,
63(2), 111-119. https://doi.org/10.1159/000099183
Kwee, L. C., Liu, D., Lin, X., Ghosh, D., & Epstein, M. P. (2008). A Powerful and Flexible
Multilocus Association Test for Quantitative Traits. The American Journal of
Human Genetics, 82(2), 386-397. https://doi.org/10.1016/j.ajhg.2007.10.010
Lee, J. D., Sun, D. L., Sun, Y., & Taylor, J. E. (2016). Exact post-selection inference,
with application to the lasso. The Annals of Statistics, 44(3).
https://doi.org/10.1214/15-AOS1371
Lee, S., Miropolsky, L., Wu, M. (2017). SKAT: SNP-Set (Sequence) Kernel Association
Test. R package version 1.3.2.1. https://CRAN.R-project.org/package=SKAT
Li, M.-X., Gui, H.-S., Kwan, J. S. H., & Sham, P. C. (2011). GATES: A Rapid and
Powerful Gene-Based Association Test Using Extended Simes Procedure.
American Journal of Human Genetics, 88(3), 283–293.
https://doi.org/10.1016/j.ajhg.2011.01.019
Li, Y. R., van Setten, J., Verma, S. S., Lu, Y., Holmes, M. V., Gao, H., Lek, M., Nair, N.,
Chandrupatla, H., Chang, B., Karczewski, K. J., Wong, C., Mohebnasab, M.,
Mukhtar, E., Phillips, R., Tragante, V., Hou, C., Steel, L., Lee, T., Garifallou, J., ...
& Keating, B. J. (2015). Concept and design of a genome-wide association
genotyping array tailored for transplantation-specific studies. Genome medicine,
7(1), 90. https://doi.org/10.1186/s13073-015-0211-x

102

Li, M., Wang, K., Grant, S. F. A., Hakonarson, H., & Li, C. (2009). ATOM: A powerful
gene-based association test by combining optimally weighted markers.
Bioinformatics, 25(4), 497–503. https://doi.org/10.1093/bioinformatics/btn641
Lim, W. H., Wong, G., Heidt, S., & Claas, F. H. J. (2018). Novel Aspects of Epitope
Matching and Practical Application in Kidney Transplantation. Kidney
International, 93(2), 314-324. https://doi.org/10.1016/j.kint.2017.08.008
Liu, Z., Barnett, I., & Lin, X. (2020). A comparison of principal component methods
between multiple phenotype regression and multiple SNP regression in genetic
association studies. The Annals of Applied Statistics, 14(1), 433–451.
https://doi.org/10.1214/19-AOAS1312
Luo, L., Boerwinkle, E., & Xiong, M. (2011). Association studies for next-generation
sequencing. Genome Research, 21(7), 1099–1108.
https://doi.org/10.1101/gr.115998.110
Luo, L., Zhu, Y., & Xiong, M. (2013). Smoothed functional principal component analysis
for testing association of the entire allelic spectrum of genetic variation. European
Journal of Human Genetics, 21(2), 217–224.
https://doi.org/10.1038/ejhg.2012.141
Marin, E. P., Cohen, E., & Dahl, N. (2020). Clinical Applications of Genetic Discoveries
in Kidney Transplantation: A Review. Kidney360, 1(4), 300–305.
https://doi.org/10.34067/KID.0000312019
McCarroll, S. A., Bradner, J. E., Turpeinen, H., Volin, L., Martin, P. J., Chilewski, S. D.,
Antin, J. H., Lee, S. J., Ruutu, T. , Storer, B., Warren, E. H., Zhang, B., Zhao, L.
103

P., Ginsburg, D., Soiffer, R. J., Partanen, J., Hansen, J. A., Ritz, J., Palotie, A., &
Altshuler, D. (2009). Donor-recipient Mismatch for Common Gene Deletion
Polymorphisms in Graft-Versus-Host Disease. Nature Genetics, 41(12), 1341-4.
https://doi.org/10.1038/ng.490
Mesnard, L., Muthukumar, T., Burbach, M., Li, C., Shang, H., Dadhania, D., Lee, J. R.,
Sharma, V. K., Xiang, J., Suberbielle, C., Carmagnat, M., Ouali, N., Rondeau, E.,
Friedewald, J. J., Abecassis, M. M., Suthanthiran, M., & Campagne, F. (2016).
Exome Sequencing and Prediction of Long-Term Kidney Allograft Function.
PLoS Computational Biology, 12(9), e1005088.
https://doi.org/10.1371/journal.pcbi.1005088
Mishra, A., & Macgregor, S. (2015). VEGAS2: Software for More Flexible Gene-Based
Testing. Twin Research and Human Genetics, 18(1), 86–91.
https://doi.org/10.1017/thg.2014.79
Moe, S. M., Long, J., Schwantes-An, T. H. L., Decker, B. S., Wetherill, L., Edenberg, H.
J., Xuei, X., Vatta, M., Foroud, T. M., & Chertow, G. M. (2018). Angiotensinrelated Genetic Determinants of Cardiovascular Disease in Patients Undergoing
Hemodialysis. Nephrology Dialysis Transplantation, 34(11), 1924-1931.
https://doi.org/10.1093/ndt/gfy191
Morris, A. A., Kalogeropoulos, A. P., Zhao, L., Owen, M., Laskar, S. R., Vega, J. D.,
Smith, A., & Butler, J. (2015). Race and Ethnic Differences in the Epidemiology
and Risk Factors for Graft Failure After Heart Transplantation. The Journal of
Heart and Lung Transplantation, 34(6), 825-831.
https://doi.org/10.1016/j.healun.2014.12.012
104

Nair, S., Eustace, J., & Thuluvath, P. J. (2002). Effect of Race on Outcome of Orthotopic
Liver Transplantation: A Cohort Study. The Lancet, 359(9303), 287-293.
https://doi.org/10.1016/S0140-6736(02)07494-9
Nair, S., & Thuluvath, P. J. (2001). Does Race-Matched Liver Transplantation Offer Any
Graft Survival Benefit?. Transplantation Proceedings 33(1-2), 1523-4.
https://doi.org/10.1016/s0041-1345(00)02581-1
Neale, B.M., Rivas, M.A., Voight, B.F., Altshuler, D., Devlin, B., Orho-Melander, M.,
Kathiresan, S., Purcell, S.M., Roeder, K., & Daly, M.J. (2011). Testing for an
unusual distribution of rare variants. PLoS Genetics, 7(3), e1001322.
https://doi.org/10.1371/journal.pgen.1001322
Ning, Y., & Liu, H. (2017). A general theory of hypothesis tests and confidence regions
for sparse high dimensional models. The Annals of Statistics, 45(1).
https://doi.org/10.1214/16-AOS1448
Oetting, W. S., Guan, W., Schladt, D. P., Leduc, R. E., Jacobson, P. A., Matas, A. J.,
Chinnakotla, S., Schröppel, B., Murphy, B. T., & Israni, A. K. (2012). Donor
Polymorphisms of Toll-Like Receptor 4 Associated With Graft Failure in Liver
Transplant Recipients. Liver Transplantation, 18(12), 1399-1405.
https://doi.org/10.1002/lt.23549
Oetting, W. S., Schladt, D. P., Guan, W., Miller, M. B., Remmel, R. P., Dorr, C.,
Sanghavi, K., Mannon, R. B., Herrera, B., Matas, A. J., Salomon, D. R., Kwok,
P.‐Y., Keating, B. J., Israni, A. K., & Jacobson, P. A. for the DeKAF Investigators
(2016). Genomewide Association Study of Tacrolimus Concentrations in African
American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
105

American Journal of Transplantation, 16(2), 574-582.
https://doi.org/10.1111/ajt.13495
Pan, W. (2009). Asymptotic tests of association with multiple SNPs in linkage
disequilibrium. Genetic Epidemiology, 33(6), 497-507.
https://doi.org/10.1002/gepi.20402
Pan, W. (2011). Relationship between genomic distance-based regression and kernel
machine regression for multi-marker association testing. Genetic Epidemiology,
35(4), 211-216. https://doi.org/10.1002/gepi.20567
Pang, P. S., Kamal, A., & Glenn, J. S. (2009). The Effect of Donor Race on the Survival
of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C.
Liver Transplantation, 15(9), 1126-1132. https://doi.org/10.1002/lt.21835
Parimi, N., Tromp, G., Kuivaniemi, H., Nien, J. K., Gomez, R., Romero, R., & Goddard,
K. A. (2008). Analytical approaches to detect maternal/fetal genotype
incompatibilities that increase risk of pre-eclampsia. BMC Medical Genetics, 9(1),
60. https://doi.org/10.1186/1471-2350-9-60
Pineda, S., Sigdel, T. K., Chen, J., Jackson, A. M., Sirota, M., & Sarwal, M. M. (2018).
Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to
Predict Antibody-Mediated Rejection Risk in Kidney Transplant. Frontiers in
Immunology, 8, 1687. https://doi.org/10.3389/fimmu.2017.01687
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D.,
Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., & Sham, P. C. (2007).
PLINK: A Tool Set for Whole-Genome Association and Population-Based
106

Linkage Analyses. The American Journal of Human Genetics, 81(3), 559-575.
https://doi.org/10.1086/519795
R Core Team (2021). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. URL: https://www.Rproject.org/.
Reddy, M. S., Varghese, J., Venkataraman, J., & Rela, M. (2013). Matching donor to
recipient in liver transplantation: Relevance in clinical practice. World Journal of
Hepatology, 5(11), 603-611. https://doi.org/10.4254/wjh.v5.i11.603
Reindl-Schwaighofer, R., Heinzel, A., Gualdoni, G. A., Mesnard, L., Claas, F. H. J., &
Oberbauer, R. (2020). Novel insights into non-HLA alloimmunity in kidney
transplantation. Transplant International, 33(1), 5–17.
https://doi.org/10.1111/tri.13546
Reindl-Schwaighofer, R., Heinzel, A., Kainz, A., van Setten, J., Jelencsics, K., Hu, K.,
Loza, B., Kammer, M., Heinze, G., Hruba, P., Koňaříková, A., Viklicky, O.,
Boehmig, G. A., Eskandary, F., Fischer, G., Claas, F., Tan, J. C., Albert, T. J.,
Patel, J., Keating, B., & Oberbauer, R. (2019). Contribution of non-HLA
incompatibility between donor and recipient to kidney allograft survival: genomewide analysis in a prospective cohort. The Lancet, 393(10174), 910-917.
https://doi.org/10.1016/S0140-6736(18)32473-5
Saxena, V., Lai, J. C., O'Leary, J. G., Verna, E. C., Brown Jr, R. S., Stravitz, R. T.,
Trotter, J. F., Krishnan, K., Terrault, N. A., & Consortium to Study Health
Outcomes in HCV Liver Transplant Recipients. (2012). Recipient-donor Race

107

Mismatch for African American Liver Transplant Patients With Chronic Hepatitis
C. Liver Transplantation, 18(5), 524-531. https://doi.org/10.1002/lt.22461
Schaid, D.J. (2010). Genomic Similarity and Kernel Methods I: Advancements by
Building on Mathematical and Statistical Foundations. Human Heredity, 70(2),
109-31. https://doi.org/10.1159/000312641
Shi, C., Song, R., Chen, Z., & Li, R. (2019). Linear hypothesis testing for high
dimensional generalized linear models. The Annals of Statistics, 47(5).
https://doi.org/10.1214/18-AOS1761
Steers, N. J., Li, Y., Drace, Z., D’Addario, J. A., Fischman, C., Liu, L., Xu, K., Na, Y.,
Neugut, Y. D., Zhang, J. Y., Sterken, R., Balderes, O., Bradbury, D., Ozturk, N.,
Ozay, F., Goswami, S., Mehl, K., Wold, J., Jelloul, F. Z., ... & Kiryluk, K. (2019).
Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection. New England
Journal of Medicine, 380 (20), 1918-1928.
https://doi.org/10.1056/NEJMoa1803731
Su, Z., Marchini, J. and Donnelly, P. (2011) HAPGEN2: simulation of multiple disease
SNPs. Bioinformatics, 27(16), 2304–2305.
https://doi.org/10.1093/bioinformatics/btr341
Sypek, M., Kausman, J., Holt, S., & Hughes, P. (2018). HLA Epitope Matching in Kidney
Transplantation: An Overview for the General Nephrologist. American Journal of
Kidney Diseases, 71(5), 720-731. https://doi.org/10.1053/j.ajkd.2017.09.021

108

Tzeng, J. Y., & Zhang, D. (2007). Haplotype-based association analysis via variancecomponents score test. American journal of human genetics, 81(5), 927–938.
https://doi.org/10.1086/521558
van de Geer, S., Bühlmann, P., Ritov, Y., & Dezeure, R. (2014). On asymptotically
optimal confidence regions and tests for high-dimensional models. The Annals of
Statistics, 42(3). https://doi.org/10.1214/14-AOS1221
Voorman, A., Shojaie, A., & Witten, D. (2014). Inference in High Dimensions with the
Penalized Score Test. ArXiv:1401.2678 [Stat]. http://arxiv.org/abs/1401.2678
Wang, K., & Abbott, D. (2008). A principal components regression approach to
multilocus genetic association studies. Genetic epidemiology, 32(2), 108–118.
https://doi.org/10.1002/gepi.20266
Wang, T., & Elston, R. C. (2007). Improved power by use of a weighted score test for
linkage disequilibrium mapping. American journal of human genetics, 80(2), 353–
360. https://doi.org/10.1086/511312
Ward, L. D., & Kellis, M. (2011). HaploReg: A Resource for Exploring Chromatin States,
Conservation, and Regulatory Motif Alterations Within Sets of Genetically Linked
Variants. Nucleic Acids Research, 40(D1), D930-D934.
https://doi.org/10.1093/nar/gkr917
Wessel, J., & Schork, N. J. (2006). Generalized genomic distance-based regression
methodology for multilocus association analysis. American journal of human
genetics, 79(5), 792–806. https://doi.org/10.1086/508346

109

Wu, C., Xu, G., & Pan, W. (2019). An Adaptive Test on High-dimensional Parameters in
Generalized Linear Models. Statistica Sinica 29, 2163-2186.
https://doi.org/10.5705/ss.202017.0354
Wu, C., Xu, G., Shen, X., & Pan, W. (2020). A Regularization-Based Adaptive Test for
High-Dimensional Generalized Linear Models. Journal of Machine Learning
Research, 21(128), 1-67. http://jmlr.org/papers/v21/18-807.html
Wu, M. C., Kraft, P., Epstein, M. P., Taylor, D. M., Chanock, S. J., Hunter, D. J., & Lin, X.
(2010). Powerful SNP-set analysis for case-control genome-wide association
studies. American journal of human genetics, 86(6), 929–942.
https://doi.org/10.1016/j.ajhg.2010.05.002
Wu, M. C., Lee, S., Cai, T., Li, Y., Boehnke, M., & Lin, X. (2011). Rare-variant
association testing for sequencing data with the sequence kernel association
test. American journal of human genetics, 89(1), 82–93.
https://doi.org/10.1016/j.ajhg.2011.05.029
Yamani, M. H., Cook, D. J., Rodriguez, E. R., Thomas, D. M., Gupta, S., Alster, J.,
Taylor, D. O., Hobbs, R., Young, J. B., Smedira, N., & Starling, R. C. (2006).
Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart
Transplant Recipients With Recurrent Rejection. The Journal of Heart and Lung
Transplantation, 25(11), 1283-1289. https://doi.org/10.1016/j.healun.2006.09.012
Yang, J. Y. C., & Sarwal, M. M. (2017). Transplant Genetics and Genomics. Nature
Reviews Genetics, 18(5), 309. https://doi.org/10.1038/nrg.2017.12

110

Zanoni, F., & Kiryluk, K. (2020). Genetic background and transplantation outcomes:
Insights from genome-wide association studies. Current Opinion in Organ
Transplantation, 25(1), 35–41. https://doi.org/10.1097/MOT.0000000000000718
Zeileis, A., & Hothorn, T. (2002). Diagnostic Checking in Regression Relationships. R
News 2(3), 7-10. URL https://CRAN.R-project.org/doc/Rnews/
Zhang, C.-H., & Zhang, S. S. (2014). Confidence intervals for low dimensional
parameters in high dimensional linear models. Journal of the Royal Statistical
Society: Series B (Statistical Methodology), 76(1), 217–242.
https://doi.org/10.1111/rssb.12026
Zhang, Y. (2017). Impact of Donor Recipient Gender and Race Mismatch on Graft
Outcomes in Patients With End-Stage Liver Disease Undergoing Liver
Transplantation. Progress in Transplantation, 27(1), 39-47.
https://doi.org/10.1177/1526924816679839
Zhang, Z., Menon, M. C., Zhang, W., Stahl, E., Loza, B.-L., Rosales, I. A., Yi, Z., Banu,
K., Garzon, F., Sun, Z., Wei, C., Huang, W., Lin, Q., Israni, A., Keating, B. J.,
Colvin, R. B., Hao, K., & Murphy, B. (2020). Genome-wide non-HLA donorrecipient genetic differences influence renal allograft survival via early allograft
fibrosis. Kidney International, 98(3), 758–768.
https://doi.org/10.1016/j.kint.2020.04.039
Zhu, L., Aly, M., Wang, H., Karakizlis, H., Weimer, R., Morath, C., Kuon, R. J., Toth, B.,
Ekpoom, N., Opelza, G., & Daniel, V. (2018). Changes of NK cell subsets with
time post-transplant in peripheral blood of renal transplant recipients. Transplant
Immunology, 49, 59-71. https://doi.org/10.1016/j.trim.2018.04.005
111

